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Distal sensory polyneuropathy (DSP), the most common neurological complication 
of HIV infection, is related to either HIV or antiretroviral therapy (ART). 
Dideoxynucleoside reverse transcriptase inhibitors such as stavudine are widely 
used in resource-poor countries and often associated with neuropathy. The 
prevalence of DSP in developed countries range from 21% to 63%; little data is 
available from Africa. We aimed to estimate the prevalence of DSP in a South 




In a cross-sectional study, DSP status was determined in 598 HIV-infected adults 
using validated tools (Brief Peripheral Neuropathy Screen and a modified version of 
the Total Neuropathy Score) to categorize subjects.  Symptomatic DSP required the 
presence of at least two neuropathic signs together with at least one symptom.  
Asymptomatic DSP required the presence of two neuropathic signs.  Clinical, 
anthropometric, quality of life and laboratory evaluations were prospectively 
performed.  Information about CD4 counts, antiretroviral therapy (ART) and 




Approximately half (49%) of the study population were diagnosed with DSP (30% 












symptomatic) compared to 63% of the ART-exposed subjects (39% symptomatic).  
Overall, subjects with DSP were older (p<0.001) and had lower CD4 counts 
(p<0.001) compared to those without neuropathy.  Previously treated TB infection 
(p<0.001) and ART use (p<0.001) showed strong associations with DSP. In 
multivariate analyses the odds (95% confidence interval) of developing DSP was 
independently associated with ART use (OR 1.7, 1.0-2.9), age (per 10 year 
increments) (OR 1.7, 1.4-2.2) and previously treated TB infection (OR 2.0, 1.3-3.0). 
Although stavudine significantly associated with DSP, the duration of exposure was 
similar irrespective of neuropathy status. Pain or paresthesiae was reported by 69% 
of those with symptomatic DSP and rated as at least moderate to severe. ART-




DSP is a clinically significant problem in urban HIV-infected Africans.  The findings of 
this study raise the possibility that with avoidance of stavudine-containing regimens 
in older subjects, especially those with a history of previously treated TB infection, 





















1.1 Distal sensory polyneuropathy background 
1.1.1 Introduction 
Human immunodeficiency virus (HIV) infection and the acquired immunodeficiency 
syndrome (AIDS) currently have a devastating impact in South Africa.  In 2006, 11% 
of the South African population or about 5.4 million South Africans was infected 
with HIV, of which about 600 000 people were suffering from AIDS (Dorrington et 
al., 2006).   
Distal sensory polyneuropathy (DSP) is recognized as the most common 
neurological complication of HIV infection (Barohn et al., 1993, Tagliati et al., 1999).  
Clinically it presents as a painful neuropathy, although autonomic dysfunction and 
thermal hypoesthesia can also occur (Devigili et al., 2008).  DSP may have a drastic 
impact on quality of life due to neuropathic pain and potentially limits activities of 
daily living (as measured by a quality of life score) due to neuropathic symptoms 
(Pettersen et al., 2006).  Amongst HIV-infected subjects, living with pain also 
increases the frequency of visits to outpatient services, putting additional strain on 
medical resources (Dobalian et al., 2004).  It may consequently also have 
psychosocial implications as a result of unemployment or depression.   
DSP in the context of HIV infection may arise either as a direct consequence of the 
viral infection itself (probably related to HIV-triggered immune activation) or as an 
adverse effect of antiretroviral therapy (ART) (see 1.1.2 Categorization of HIV-
associated DSP).  We refer to the former as HIV-DSP and the latter as antiretroviral 
toxic neuropathy (ATN).  The more generic term DSP is used when the distinction 
between these two pathophysiological mechanisms is not being made. 
Current treatment modalities for DSP are also frequently ineffective.  Agents such 












antidepressants offer relief only in a minority of patients (Wulff et al., 2000).  
Anticonvulsants such as gabapentin, which has shown therapeutic benefit, are not 
available in the state healthcare sector (Verma et al., 2004).  Lamotrigine, which is 
widely available, has only limited efficacy (Silver et al., 2007), and carbamazepine is 
contraindicated with antiretroviral therapy. 
No data on either the prevalence of HIV-associated DSP or associations thereof in 
African subjects have been published to date.  As DSP may impose a significant 
problem on our HIV-infected population and on already-limited medical resources, 
we aimed to describe the prevalence of HIV-associated DSP in an urban African 
population and investigate the association between HIV-associated DSP and 
possible risk factors.  We also investigated the association between selected 
functional cytokine gene promoter polymorphisms and the occurrence of HIV-
associated DSP. 
 
1.1.2 Categorization of HIV-associated DSP 
HIV-associated DSP can be categorized into two groups based on etiology.  It can 
occur either as a direct consequence of HIV infection (HIV-DSP) or related to 
antiretroviral therapy (ART), termed antiretroviral toxic neuropathy (ATN).  ATN is 
clinically and electrophysiologically indistinguishable from HIV-DSP (Cherry et al., 
2006), although early studies suggest a more rapid onset and progression of ATN 
compared to HIV-DSP, particularly in individuals with moderate to severe immune 
suppression and at higher doses of neurotoxic drugs (Berger et al., 1993).  HIV-
associated DSP is a predominantly small fibre length-dependant sensory 
polyneuropathy that may manifest as pain, paresthesiae, numbness or cramps.  
Symptoms are bilateral and symmetrical, and predominantly affect the lower legs 
although the hands may also become involved as the disease progresses.   
HIV-associated DSP can also be classified based on the presence or absence of 
symptoms.  Individuals with symptoms of small fibre dysfunction in addition to signs 












without symptoms are referred to as having asymptomatic DSP (ADSP).  Signs of 
DSP would be either deep tendon reflex changes with a distal-to-proximal gradient 
of hypo- or areflexia, as well as vibration sense loss or pinprick sensation loss in a 
glove-and-stocking distribution.  Motor weakness is an uncommon finding, and 
usually only affects the intrinsic foot muscles (Wulff et al., 2000).  It is not yet clear 
whether the development of asymptomatic- and symptomatic DSP represent a 
continuum from a neuropathy-free state.  Schifitto et al. demonstrated that a 
diagnosis of asymptomatic DSP was not a significant predictor of subsequent 
development of symptomatic DSP (Schifitto et al., 2002).  Morgello et al. found that 
risk factors such as demographic variables, dideoxynucleoside reverse transcriptase 
inhibitor (dNRTI) exposure, plasma viral load and CD4
+
 count did not significantly 
differ between individuals with symptomatic or asymptomatic DSP (Morgello et al., 
2004).  Epidermal nerve fibre density (EFND, see 1.1.7 Diagnostic Methods) 
quantification has also been used in an attempt to better define asymptomatic DSP.  
Herrmann et al. showed that subjects with a diagnosis of both symptomatic- or 
asymptomatic DSP had reduced ENFDs compared to subjects without DSP and HIV 
negative controls (Herrmann et al., 2004) and also that individuals with reduced 
ENFD have a 14-fold increased risk of developing symptomatic DSP (Herrmann et 
al., 2006). 
 
1.1.3 Pathogenesis of HIV-associated DSP 
HIV-associated neuropathy is a small fibre neuropathy that predominantly affects 
small unmyelinated C-fibres and possibly thinly myelinated Aδ-fibres (Devigili et al., 
2008).  A ‘dying back’ pattern of degeneration is seen in sensory neurons, which is 
similar to the degeneration seen in diabetic and alcoholic polyneuropathies (Melli et 
al., 2006).  Clinically, a length-dependant pattern of sensory loss, with or without 












1.1.3.1 Pathogenesis of HIV-DSP 
Several mechanisms have been proposed for the pathogenesis of HIV-DSP.   Reports 
of axonal localizing HIV-1 in peripheral nerve tissue are limited, and in situ 
hybridization has detected HIV-1 RNA in only a few isolated perivascular 
mononuclear cells in dorsal root ganglia (DRG) in a minority of patients with AIDS 
(Yoshioka et al., 1994).  Very few of these patients had any evidence of DSP 
(Yoshioka et al., 1994).  Since direct neurotoxicity seemed unlikely as a primary 
cause for DSP, the focus shifted to the investigation of secreted viral proteins and 
cytokine-mediated injury.   
HIV entry into target cells are facilitated by the membrane-bound chemokine 
receptors CXCR4 and CCR5 (Keswani et al., 2003).  These receptors can also be 
ligated by viral proteins, as it has been shown that the HIV-1 envelope glycoprotein 
120 (gp120) in its soluble form can bind to CXCR4 and CCR5 receptors on axonal 
membranes and exert pathologic effects in nerves and DRGs (Keswani et al., 2003, 
Melli et al., 2006).   
CXCR4 and CCR5 receptors are present on a variety of cell types, including Schwann 
cells.  Exposure of Schwann cells to gp120 causes ligation of CXCR4 receptors and 
subsequent secretion of chemokines such as RANTES (regulated upon activation, 
normal T-cell expressed and secreted).  RANTES causes neurons to release tumour 
necrosis factor alpha (TNF-α), which induces neuronal apoptosis via TNF-receptor-1 
signalling (Keswani et al., 2003).  Both RANTES and TNF-α previously have been 
linked to neuropathic pain, which may explain the painful nature of DSP (Keswani et 
al., 2003).   
In vitro experiments have shown gp120 to be pathogenic both to sensory neuronal 
cell bodies in the presence of Schwann cells, and also directly to nerve axons (Melli 
et al., 2006, Keswani et al., 2003).  In cell bodies, the binding of gp120 to receptors 
on Schwann cells caused a reduction in neurite branching and neurite length per 
neuron, as well as neuronal mitochondrial membrane depolarization, the latter 
begin a crucial event early in the process of programmed cell death, or apoptosis 












mitochondrial dysfunction and ultimately in decreased axon length, but not 
apoptosis (Melli et al., 2006).  Similar dysfunction of axonal mitochondria has also 
been demonstrated in diabetic polyneuropathy (Melli et al., 2006).   
The proposed sources of gp120 are HIV-infected macrophages infiltrating DRGs and 
peripheral nerve axons, or circulating gp120 due to the absence of an appreciable 
blood-nerve barrier at terminal axons (Keswani et al., 2003).  In support of the 
causative role of gp120 in DSP, studies have demonstrated a decrease in ENFD (see 
1.1.7 Diagnostic Methods) in rats treated with perineural gp120 (Wallace et al., 
2007).   
In conclusion, the pathogenesis of HIV-DSP is not fully understood but viral protein 
and host cytokine responses may participate in a complex interplay resulting in 
nerve fibre toxicity and loss. 
 
1.1.3.2 Pathogenesis and history of Antiretroviral Toxic Neuropathy (ATN) 
The exact pathogenesis of ATN is not yet established.  It is proposed that ATN 
caused by the dNRTI-class of drugs may occur through dysfunction or toxicity of 
mitochondrial metabolism (Berger et al., 1993, Keswani et al., 2002).  Based on an 
animal model investigating neurotoxic antiretroviral drugs, it has been proposed 
that ATN may also be a synergistic consequence of both HIV infection and ART 
neurotoxicity (Pettersen et al., 2006). 
Dideoxynucleoside analogues contain azido groups that compete with natural 
thymidine triphosphate as substrates of DNA polymerase γ, the host enzyme 
responsible for mitochondrial DNA synthesis.  This competitive inhibition of DNA 
polymerase γ may disrupt mitochondrial DNA (mtDNA) synthesis and ultimately 
result in decreased levels of mtDNA (in Hung et al., 2008).  Plasma mtDNA depletion 
was not found to be present in all subjects with clinical evidence of mitochondrial 
toxicity (including those with peripheral neuropathy), and surprisingly, found to be 
increased in subjects exposed to dNRTIs for more than 5 years (McComsey et al., 












overreplication of mtDNA due to mitochondrial dysfunction after long-standing 
dNRTI exposure (McComsey et al., 2005).   
ATN was the dose-limiting toxicity in phase I trials of several agents used to treat 
HIV infection.  Stavudine (d4T) (Browne et al., 1993), didanosine (ddI) (Lambert et 
al., 1990) and zalcitabine (ddC) (Berger et al., 1993), all dNRTIs, have been shown to 
cause ATN (Cherry et al., 2006, Smyth et al., 2007).  In phase I studies on stavudine, 
ATN occurred as early as five weeks after exposure to the drug (Browne et al., 
1993), and symptomatic peripheral neuropathy was the dose-limiting toxicity 
associated with increased doses and more frequent dosing intervals (Browne et al., 
1993, Berger et al., 1993).   
A WHO survey on ART use in resource-limited countries showed that 69% of first-
line ART regimens included stavudine, representing 53% of all patients on ART in 23 
developing countries, or an estimated 851 000 individuals (Renaud-Théry et al., 
2006).  Stavudine is still widely used as a first-line agent in South African ART 
regimens, and can thus still have a considerable impact on prevalence rates of ATN 
in our HIV-infected population.  
In keeping with the WHO recommendations (Antiretroviral Therapy 
Recommendations [WHO], 2006), South African ART regimens do not contain more 
than one dNRTI-class drug due to possible or probable overlapping toxicity (Renaud-
Théry et al., 2006).  The combination of stavudine and didanosine compared to 
stavudine monotherapy has an increased DSP prevalence of 2.5-fold (Moore et al., 
2000).   Combination therapy compared to didanosine monotherapy increased DSP 
prevalence 3.5-fold (Moore et al., 2000), and didanosine is occasionally used as a 
second-line agent in South Africa (National Antiretroviral Treatment Guidelines 
2004).  Although fewer patients are on second-line ART than first-line ART, 60% of 
individuals in developing countries are still receiving a ddI-containing second-line 
ART regimen (Renaud-Théry et al., 2006).     
It is not yet clear what duration of dNRTI exposure confers maximum risk of 
developing toxicity to nerves, and conversely, not all studies have shown an 












Longitudinal studies have shown that exposure to dNRTIs were associated with a 
decreased risk of developing DSP and even a trend towards protection against 
symptomatic DSP (Schifitto et al., 2002, Simpson et al., 2006).  The authors 
suggested that, although seemingly paradoxical, maintaining a certain degree of 
immune function through dNRTI use possibly outweighs the drugs’ potential 
neurotoxicity (Schifitto et al., 2002).  More recent studies confirmed that neither 
exposure to dNRTIs at baseline nor their cumulative use was associated with 
progression of neuropathy (Simpson et al., 2006, Arenas-Pinto et al., 2008).  Based 
on these findings, several researchers have hypothesized that dNRTI neurotoxicity 
occurs early during the agents’ use in susceptible subjects who then discontinue the 
agents, as well as a survival bias in those subjects who tolerate the drug’s effects 
(Simpson et al., 2006, Hung et al., 2008, Arenas-Pinto et al., 2008).   
Arenas-Pinto et al. found that the risk for DSP peaked at 90 days of exposure to 
dNRTIs, where after the risk decreased (Arenas-Pinto et al., 2008). It was also 
suggested that individuals who remain neuropathy free after 12 months of 
exposure to dNRTIs will tolerate continued therapy without an increased risk of 
worsening neuropathy signs or symptoms (Hung et al., 2008).  Morgello et al. 
concluded that dNRTI use per se in the era of highly active antiretroviral therapy 
(HAART) was not a risk factor for the development of DSP, but that its contribution 
to the development of DSP is reliant on the underlying metabolic and immunologic 
status of the individual (Morgello et al., 2004). 
Other classes of ART drugs, such as the protease inhibitors (indinavir, saquinavir and 
ritonavir - Pettersen et al., 2006, Smyth et al., 2007), have also been associated with 
the development of neuropathy. Fusion inhibitors such as enfuvirtide are new drugs 
used for the treatment of HIV infection and are also currently under investigation 












1.1.4 Risk factors for HIV-associated DSP 
Known etiologies for small fibre neuropathies other than HIV or ART include 
diabetes and the pre-diabetic state, vitamin B12 deficiency, hypothyroidism, statin 
therapy, isoniazid therapy, immune-mediated and connective tissue disorders, 
paraneoplastic syndromes and opportunistic infections such as cytomegalovirus 
(CMV) infection (Tagliati et al., 1999, Pardo et al., 2001, Devigili et al., 2008).  In a 
proportion of subjects a cause cannot be identified. 
HIV-associated DSP has previously been associated with older age, patient height 
and BMI, poor nutrition, hepatitis C co-infection, plasma lactate level and advanced 
HIV disease with CD4 counts below 200 cells/µl (Tagliati et al., 1999, Childs et al., 
1999, Morgello et al., 2004, Cherry et al., 2005, Cherry et al., 2006, Simpson et al., 
2006, Smyth et al., 2007).   
Demographic variables such as male sex and whit  race have been reported to be 
associated with DSP (Tagliati et al., 1999, Morgello et al., 2004), but not consistently 
(Schifitto et al., 2002).  Although age older than 40 years is generally accepted as 
being particularly important in the development of DSP (Morgello et al., 2004, 
Cherry et al., 2006), one study reported that it was only associated with the 
presence of DSP, not the progression thereof (Simpson et al., 2006).  When 
measured in 5-year increments, older age did not predict a worsening in the 
outcome measure (Total Neuropathy Score, see 1.1.7 Diagnostic Methods) over a 
48 week period (Simpson et al., 2006).   
As a measure of HIV severity, high plasma HIV RNA levels have been associated with 
the presence and severity of DSP (Simpson et al., 2002).  Studies reported higher 
HIV load and lower CD4 counts to be predictors of particularly symptomatic DSP 
(Childs et al., 1999, Watters et al., 2004).  Nadir CD4 counts was found to be a 
predictor of HIV-associated DSP, but not the current CD4 count (at the time of 
study) in a cross-sectional cohort (Lichtenstein et al., 2005).  Either of these 
measures of HIV severity (CD4 counts and viral load) have failed to correlate with 
either the presence of progression of neuropathy consistently, although selection 












HIV-associated neuropathy on about 800 North American subjects reported that no 
individuals with CD4
+
 counts greater than 300 cells/µl had any evidence of 
neuropathy (Barohn et al., 1993).   
The role of alcohol exposure as a risk factor is poorly defined at present.  Studies 
have reported a positive association between alcohol use and the development of 
symptomatic DSP (Morgello et al., 2004) while others failed to find an association, 
and another study reported that alcohol use was more prevalent in neuropathy-free 
subjects than in subjects with neuropathy (Pettersen et al., 2006).  One study found 
impairment in physical function to be a predictor for symptomatic DSP (Schifitto et 
al., 2002) but it seems more likely that the association comes from a limitation in 
activities of daily living due to painful neuropathy. 
Vitamin B12 levels have not been associated significantly with DSP in HIV-infected 
individuals (Tagliati et al., 1999).  A recent study from an urban African population 
on TB therapy reported a 57% reduction in peripheral neuropathy in those 
supplemented with various micronutrients (including vitamin B complex), 
irrespective of HIV status (Villamor et al., 2008).  
 
1.1.5 Prevalence of HIV-associated DSP in developed countries 
The prevalence of HIV-associated DSP (combined HIV-DSP and ATN) from cross-
sectional studies has been reported in the literature to range from 21% (Marra et 
al., 1998) to 53% and 63% (Morgello et al., 2004, Cherry et al., 2006).  Longitudinal 
studies report a high conversion rate from baseline, as 34% to 52% of neuropathy 
free patients developed symptomatic DSP at 1 year follow-up (Schifitto et al., 2002, 
Simpson et al., 2006).  In these studies, dNRTI use ranged from 29% to 83%.  It is 
important, however, to keep in mind that some of the published studies were based 
on highly selected populations, such as a referral neurology clinic (Simpson et al., 
2006) or the HIV Brain Bank project (Morgello et al., 2004) and might not be truly 












A population-based (non-referral) study from a military medical centre reported a 
16% DSP prevalence rate – the majority of subjects had early HIV disease as the 
diagnosis was made in a mandatory screening program, and therefore may be more 
representative of the background prevalence in a general population of young men 
(Barohn et al., 1993). 
Since the advent of HAART in 1996, incidence rates of CNS opportunistic infections 
and dementia have decreased (Sacktor et al., 2001, Brodt et al., 1997) but the 
incidence of HIV-associated DSP has increased with rates exceeding 50% per year 
(Bacellar et al., 1994, Morgello et al., 2004, Watters et al., 2004).  Although it was 
thought that development and progression of neuropathy correlated with 
progression of HIV disease and that longer survival with severe immunosuppression 
might explain the observed increases in incidence rates, the effect remained after 
adjusting for CD4 cell count.   
 
1.1.6 Data on HIV-associated DSP in Africa and other developing countries 
Limited data is available from African populations.  A Medline search (using ‘Africa’, 
‘HIV’ and ‘neuropathy’ as parameters) failed to show studies documenting data of a 
systematic examination for neuropathy using validated clinical tools, although a few 
reports mentioning neuropathy prevalence in the context of adverse effects of ART 
were found.  In the majority of these studies, diagnostic criteria for neuropathy 
were not defined and the diagnosis was frequently based mainly on symptom 
reporting (Jamisse et al., 2007, Hawkins et al., 2007).  Jamisse et al. investigated 
ART-related toxicities in urban pregnant women in Mozambique, and found an 18% 
symptomatic neuropathy prevalence rate based on self-reporting of acute 
numbness, pain or paresthesiae with no reference made to the presence of signs 
(Jamisse et al., 2007). Such symptoms were not associated with CD4
+
 count, and 
neither with AZT- or stavudine-containing ART regimens (Jamisse et al., 2007).  A 
study on ART tolerability in an urban Kenyan population reported a 21% HIV-
associated neuropathy prevalence, but no reference as to which criteria were used 












the tolerability of non-dNRTI regimens in an urban South African cohort and 
reported a DSP incidence of 8 per 100-person years.  The diagnosis was based on 
reported symptoms (numbness or paresthesiae in the lower limbs), or the presence 
of decreased sensation to light touch or attenuated ankle deep tendon reflexes on 
physician examination (Hoffmann et al., 2008).   A large multicentre study from the 
Asia-Pacific region reported a 19.7% prevalence of symptomatic DSP based on the 
presence of symptoms and at least 1 neuropathic sign consistent with DSP (Wright 
et al., 2008). 
 
1.1.7 Diagnostic methods 
Various neurophysiologic and neuropathologic techniques have been used in the 
diagnosis of small fibre neuropathy.  Commonly used tools include questionnaires 
on sensory symptoms (for symptomatic DSP), sensory signs, ankle deep tendon 
reflexes, quantitative sensory threshold testing (QST), sural sensory nerve action 
potentials (SNAP) and epidermal nerve fibre density (ENFD) quantification on skin 
biopsy.  Routine nerve conduction studies cannot reliably identify pure small fibre 
neuropathy due to the lack of myelination of small sensory nerve fibres (Lauria et 
al., 2008). 
There is not currently a recognised clinical definition for small fibre neuropathy for 
use in research trials, which poses a problem in comparing reported neuropathy 
rates and risk factors.  Neurophysiologic studies such as QST and SNAPs require 
specialized equipment and thus have practical limitations in field studies in 
resource-poor settings.  ENFD measurements on skin biopsy can be reliably 
quantified and is an objective measure of small fibre neuropathy in the clinical 
setting (Lauria, 2005), but is impractical in field studies.  Because of these 
limitations, field or epidemiological studies therefore rely on the availability and 
validity of clinical tools to detect DSP, and even more so in resource-limited settings 













1.1.7.1 Proposed definitions 
In 2005, a set of definitions for distal symmetrical polyneuropathy for clinical 
research were proposed by a collaboration between the American Academy of 
Neurology, the American Association of Electrodiagnostic Medicine and the 
American Academy of Physical Medicine and Rehabilitation (England et al., 2005).  
This definition is dependent on the presence of neuropathic symptoms, including 
numbness, burning, paresthesiae, dysesthesiae and allodynia, and the presence of 
signs, including attenuated deep tendon reflexes, decreased pin sensation or 
decreased vibration sense, recognising that deep tendon reflexes abnormalities may 
not be necessary for a diagnosis of small fibre neuropathy (England et al., 2005).  
Different definitions for clinical research studies and epidemiologic studies were 
proposed, and definitions were ranked by estimated ordinal likelihood of disease.   
For field studies, the highest ranked definitions included a combination of 
symptoms, attenuated deep tendon reflexes and decreased sensation (pin or 
vibration), although the task force recognized that pure small fibre neuropathy may 
not necessarily have abnormal deep tendon reflexes.  The collaboration concluded 
that evidence-based literature for pure small fibre neuropathy is insufficient at 
present to provide an adequate case definition (England et al., 2005).   
 
1.1.7.2 Epidermal Nerve Fibre Density (ENFD) 
Skin biopsy with determination of ENFD is the most reliable method of diagnosing 
small fibre neuropathy and has been used in the examination of patients with 
suspected small fibre neuropathy since the availability of antibodies against protein-
gene-product 9.5 (PGP9.5) which allows immunocytochemical staining of the 
extensive innervation of the epidermis (McArthur et al., 1998, Lauria, 2005, Devigili 
et al., 2008).  This technique was also used to demonstrate that small fibres, which 
penetrates to the stratum spinosum layer in the epidermis (McArthur et al., 1998), 
undergo morphologic change early in the course of neuropathies associated with 












neuropathy (Herrmann et al., 2006, Devigili et al., 2008).  Studies showed a 
significant reduction in the ENFD in subjects with small fibre neuropathy in both the 
thigh and distal leg, but as expected more fibre loss in the distal leg due to the 
“dying-back” pattern of degeneration, and a negative correlation was demonstrated 
between ENFD and neuropathic pain intensity as measured by a validated indicator 
of pain severity (Zhou et al., 2007, Polydefkis et al., 2002).  As briefly mentioned 
earlier, it has been shown that a reduction in ENFD confers a 14-fold increased risk 
of developing symptomatic DSP (Herrmann et al., 2006).   
Despite the proven accuracy of ENFD quantification, its use is unfortunately limited 
in a resource-poor research settings.  Skin sampling by punch biopsy can be done 
with little pain or discomfort in the clinic, but expertise on the histological 
techniques is not widely available.   
 
1.1.7.3 Clinical tools 
The Brief Peripheral Neuropathy Screen (BPNS) (see Appendix A) is a screening tool 
for DSP that was developed for the clinical diagnosis of HIV-associated neuropathies 
and has been used by the AIDS Clinical Trial Group (North America) in study 
protocols (McArthur, 1998, Cherry et al., 2005).  A diagnosis of symptomatic DSP on 
an adapted version of the BPNS (only requiring 1 sign for the diagnosis of 
symptomatic DSP) has been shown to correlate well with decreased ENFD 
measurements as well as increased thresholds on QST as a diagnostic tool for DSP 
(Cherry et al., 2005).  The BPNS was also validated to differentiate between cases 
with symptoms and signs consistent with DSP, and those only reporting symptoms 
without the presence of signs.  The latter group do not meet the criteria for DSP on 
the BPNS (previously labeled as being indeterminate), and was shown to have ENFD 
and QST measurements similar to subjects without symptoms or signs suggestive of 
DSP (Cherry et al., 2005). 
The Total Neuropathy Score (TNS) is another scoring system for distal length-












peripheral nerve function with excellent inter- and intrarater reliability (Cornblath 
et al., 1999).  It was validated in diabetic polyneuropathy against various other 
recognised clinical measures of peripheral nerve function, as well as sensory- and 
motor nerve biopsies, and can also be used to measure the progression of 
neuropathy longitudinally (Cornblath et al., 1999).  A reduced version of the TNS 
was developed specifically for the diagnosis of chemotherapy-induced peripheral 
neuropathy (CIPN), a painful sensory polyneuropathy (Cavaletti et al., 2003).  This 
version did not included vibration QST testing, and also did not score autonomic or 
motor symptoms, but was validated against the same clinical tools as the original 
TNS (Cavaletti et al., 2003).  In addition it showed good concordance with ENFD 
measurement, endorsing it as a reliable tool in screening for sensory 
polyneuropathies (Zhou et al., 2007).   
Another modified version of the TNS was developed, only incorporating clinical 
parameters (TNSc).  This scoring system grades symptoms (sensory, motor and 
autonomic) as well as clinical signs, namely pin sensibility, vibration sensibility, deep 
tendon reflexes and strength.  It was developed as a tool that could be applied at 
the bedside without the need for special equipment.  The TNSc was validated in a 
multicentre study against the same scoring systems as the original TNS and the 
reduced TNS in the diagnosis of CIPN, and was found to have good correlation with 












1.1.8 Aims  
Concerns exist about the frequent use of stavudine in a population already at risk of 
developing polyneuropathy based on the high prevalence of malnutrition, alcohol 
use, prior anti-tuberculous therapy and HIV infection itself.  Interaction of these risk 
factors can possibly lead to an epidemic of antiretroviral toxic neuropathy, and 
these concerns have provided the impetus for this cross-sectional study with the 
following aims: 
1) To establish the prevalence of neuropathy amongst HIV-infected subjects 
including both HIV-DSP and ATN, in a community-based cohort, and 
 
2) to identify relevant risk factors that may contribute to the development of 












1.2 Tumour necrosis factor background 
1.2.1 Introduction 
Tumour necrosis factor alpha (TNF-α) is a potent immune modulator and pro-
inflammatory cytokine, which has been implicated in the pathogenesis of 
autoimmune and infectious diseases (Herbein and Khan 2008, in Abbas et al., 2007).  
It was originally identified as a substance present in the serum of animals treated 
with lipopolysaccharide (LPS, a bacterial endotoxin) which caused the necrosis of 
tumours in vivo (in Thomson and Lotze, 2003).  In low concentrations, it confers 
resistance to certain types of infection, but at higher levels (as caused by severe 
infection) it can be the cause of pathological complications (in Thomson and Lotze, 
2003, in Abbas et al., 2007). 
 
1.2.2 Gene and protein structure 
TNF-α is synthesized as a 26 kilodalton (kD) non-glycosylated type II membrane 
protein and is expressed as a homotrimer on the membranes of mononuclear 
phagocytes (in Abbas et al., 2007, in Thomson and Lotze, 2003).  The membrane 
form of TNF-α is cleaved by a membrane-associated metalloproteinase disintegrin 
named tumour necrosis factor-alpha converting enzyme (TACE), releasing a 17-kD 
polypeptide.  Circulating TNF-α is a 51-kD protein formed by polymerization of three 
of these polypeptides.  It assumes a triangular shape, and can simultaneously bind 
to three receptor molecules (in Abbas et al., 2007).  
 
1.2.3 Function 
TNF-α exerts effects on a various immune cell types, vascular endothelium, 
adipocytes, fibroblasts as well as various organ systems (in Thomson and Lotze, 
2003).  Its principal function however, is stimulating the recruitment of 
mononuclear cells and neutrophils to sites of inflammation, and the activation of 












these activated macrophages and vascular epithelium expresses adhesion 
molecules for leukocytes resulting in leukocyte chemotaxis (in Abbas et al., 2007, in 
Thomson and Lotze, 2003).  TNF-α also stimulates the release of IL-1 by 
mononuclear phagocytes, which functions much like TNF-α itself, and stimulates the 
microbiocidal activity of neutrophils and macrophages (in Abbas et al., 2007).   
 
1.2.4 TNF receptors 
TNF-α receptors are part of a large family of type I membrane glycoproteins (the 
TNF-R family) and are present on almost all cell types (in Thomson and Lotze, 2003).  
Two receptors are known, a 55kD receptor named TNF-RI (or p55) and a 75kD 
receptor named TNF-RII (or p75).   Signalling via TNF-RI receptor is not clearly 
understood, as cytokine binding of TNF-RI can induce either a death signal by 
recruitment of an adapter protein that activates caspases and triggers apoptosis, or 
can activate transcription factors (in Abbas et al., 2007).  Cytokine binding to TNF-RII 
leads to the recruitment of proteins called TNF-receptor associated factors (TRAFs) 
to the cytoplasmic domains of the receptor, which in turn activates transcription 
factors such as nuclear factor κB (NF-κB) and activation protein-1 (AP-1) (in Abbas et 
al., 2007) 
 
1.2.5 TNF-α expression, regulation and its role in HIV infection 
TNF-α is secreted mainly by mononuclear phagocytes, although antigen-stimulated 
T cells, natural killer (NK) cells, eosinophils, basophils, mast cells and various other 
non-immune cells also can be a source (in Thomson and Lotze, 2003).  Release of 
LPS is the most potent stimulus for TNF-α production, which is why very high levels 
of TNF-α is seen in gram-negative sepsis.  TNF-α production may also be stimulated 
by infection with viruses, parasites and mycobacteria (in Thomson and Lotze, 2003).  
TNF-α synthesis is augmented by IFN-γ which is also produced by T cells and NK cells 












of the interleukin family, including IL-10 (see 1.3.1 IL-10 Introduction), and various 
other anti-inflammatory cytokines (in Thomson and Lotze, 2003). 
HIV-infection causes a state of chronic immune activation, characterized by a 
gradual increase in pro-inflammatory cytokines with disease progression (Antoni et 
al., 1995, Herbein and Khan 2008, Douek et al., 2009).  In the earlier stages of HIV-
infection increased expression of membrane-bound TNF-α and membrane-bound 
TNF receptors on lymphocytes and monocytes are seen when compared to healthy 
controls (Hestdal et al., 1997, Herbein and Khan 2008).  In addition, HIV proteins 
also regulate TNF expression through targeting of the TNF receptor pathway 
(Herbein and Khan 2008).  As the disease progresses towards AIDS, increasing levels 
of soluble TNF components were demonstrated in the sera of subjects (de Olivera 
Pinto et al., 2002, Herbein and Kahn 2008).   
 
1.2.6 TNF-α and the peripheral nervous system 
Infiltration of the dorsal root ganglia by mononuclear cells and the presence of TNF-
α and other cytokines therein have been demonstrated in patients with AIDS 
(Nagano et al., 1996).  In addition, increased levels of TNF-α have previously been 
documented in peripheral nerves from patients with HIV-DSP compared to controls 
(Tyor et al., 1995). 
TNF-α has been associated with non-HIV painful neuropathies when compared to 
patients with painless neuropathy and healthy controls (Uçeyler et al., 2007).  The 
increase in serum levels of TNF-α in subjects with neuropathy was not associated 
with a specific etiological subgroup, and was equally raised between inflammatory 












1.2.7 Expression regulated by genotypes 
It has been shown that up to 60% of the variation of TNF-α serum level is genetically 
determined (Westendorp et al., 1997).  Nine single nucleotide polymorphisms 
(SNPs) in the TNF-α promoter are known, although not all appear to be functional 
(Bidwell et al., 1999, Jeong et al., 2004).  The TNF-α –308G→A SNP (rs1800692, 
Entrez SNP Database) involves the substitution of guanine (G) for adenine (A), and 
has frequently been investigated in relation to association with inflammatory and 
infectious diseases (Entrez SNP Database, in Bidwell et al., 1999).  Alleles with the 
polymorphism are referred to in the literature as TNF2 alleles (–308G→A), whether 
heterozygous or homozygous, and are associated with a higher rate of gene and 
protein transcription and ultimately higher levels of circulating TNF-α (Gonzalez et 
al., 2003, Jeong et al., 2004).   
The A-allelic frequency reported for African populations (6% – 8%) are lower 
compared to African-American (12% - 21%) and Caucasian populations (10% - 24%) 
(Allen, 1999, Zabaleta et al., 2008, Entrez SNP Database).  Interestingly, there are no 
reported African subjects homozygous for the TNF2 allele on the NCBI SNP database 
compared to about 5% amongst African-Americans (Entrez SNP Database).  
 
1.2.8 TNF-α promoter SNP association studies 
Associations have been reported between the TNF2 allele and inflammatory 
conditions such as rheumatoid arthritis, inflammatory bowel disease, systemic 
lupus erythematosus, primary sclerosing cholangitis, pneumoconiosis, asthma and 
dermatitis herpetiformis, as well as infective conditions such as malaria, cerebral 
malaria and leprosy (in Bidwell et al., 1999, Gonzalez et al., 2003, Ferguson et al., 
2008).  The TNF2 allele was also associated with severe infections in elderly Italians 
(Cipriano et al., 2005). 
The TNF2 allele was associated with a significantly increased risk of neurological 
complications due to malaria in Gambian children, as carriers of the allele had a 












to non-carriers of the TNF2 allele (McGuire et al., 1994). In HIV-infected individuals 
the presence of a TNF2 allele conferred a five-fold increased risk of developing HIV-
associated dementia (Quasney et al., 2001).   
Limited data exists on a possible association between TNF-α promoter genotypes or 
serum levels of TNF-α and the prevalence of peripheral neuropathy.  A recent study 
failed to show a significant association between the TNF-α -308G→A SNP and 
painful neuropathies (p=0.12) in a small series of predominantly Caucasian ART-
exposed patients (Cherry et al., 2008b).  However, in this cohort another TNF-α 
promoter SNP (-1031 T→C) was associated with a 14-fold increase (p=0.02) in odds 
of developing symptomatic ATN (Cherry et al., 2008b).  As a pilot study, we will 
assess whether an association exists between the presence of the TNF2 allele and 













1.3 Interleukin-10 background 
1.3.1 Introduction 
Interleukin-10 (IL-10) is an anti-inflammatory cytokine and key regulator of immune 
responses.  Because of its function, it was originally described as cytokine synthesis 
inhibitory factor (CSIF) by Fiorentino et al. in 1989 (summarized in Thomson and 
Lotze, 2003).  The main function of IL-10 is to inhibit monocyte- and macrophage 
production of a range of pro-inflammatory cytokines, including TNF-α and IL-12 (in 
Abbas et al., 2007).  IL-12 reduction is vital to the down-regulation of the 
inflammatory response, as it is a critical stimulus for production of interferon-γ (IFN-
γ), the principal macrophage-activating cytokine (in Thomson and Lotze, 2003, in 
Abbas et al., 2007).  IL-10 also indirectly suppresses the inflammatory response by 
inhibiting dendritic cell stimulation of IFN-γ and by inhibition of antigen 
presentation and chemokine expression by mononuclear phagocytes (in Thomson 
and Lotze, 2003). 
 
1.3.2 Gene and protein structure 
Human IL-10 is an 18 kD non-glycosylated polypeptide, for which the encoding gene 
is located on chromosome 1.  Structurally it is a tight non-covalent homodimer, 
where each monomer consists of six α-helices (termed A through F) that interact 
with the helices from the accompanying monomer to form two interpenetrating 
domains (in Thomson and Lotze, 2003). 
 
1.3.3 Expression and regulation 
IL-10 is secreted mainly by activated macrophages but can also be secreted by T-
lymphocytes, B-lymphocytes, mast cells, eosinophils and NK cells (in Thomson and 
Lotze, 2003, in Abbas et al., 2007).  Stimuli required for the expression of IL-10 is 
cell-type specific, and represents a complex interplay between infectious agents, 












Production of IL-10 is induced by various pathogens, including HIV infection, which 
can directly activate monocytes and/or macrophages (Brigino et al., 1997, in 
Thomson and Lotze, 2003).  Production of IL-10 is regulated predominantly by other 
cytokines, but also by hormones or arachidonic acid derivatives in situations of 
severe stress or infection (in Thomson and Lotze, 2003).  Cytokines such as IL-4, IL-
13 and IFN-γ inhibit IL-10 production, whereas IL-1, IL-2, IL-3, IL-6, IL-7, IL-12 and IL-
15 all induce IL-10 production in target cells (in Thomson and Lotze, 2003).  TNF-α 
also induces IL-10 production in monocytes and appeared to show a greater 
influence on IL-10 production when compared to the effects of IL-1 and IL-6 
(Wanidworanun and Strober, 1993). 
 
1.3.4 IL-10 is implicated in the pathogenesis of disease 
High levels of IL-10 have been documented in association with various diseases, 
including infective conditions such as malaria (Peyron et al., 1994) and bacterial 
meningitis (Frei et al., 1993), as well as malignancies such as cervical cancer 
(Stanczuk et al., 2001).  Westendorp et al. demonstrated a 20-fold increase in the 
risk for fatal outcome from meningococcal disease in subjects with high IL-10 
production compared to those with low IL-10 production (Westendorp et al., 1997).   
In peripheral nerves, between two and four days after injury, IL-10 is synthesised by 
Schwann cells and invading macrophages as a consequence of Wallerian 
degeneration (Jander et al., 1996).  In an animal (rat) model of chronic constriction 
injury with neuropathic pain, a progressive increase in IL-10 levels at the injury site 
was associated with a resolution of hyperalgesia (Okamoto et al., 2001).  Further, 
local application of a low concentration of IL-10 to transected sciatic nerve in a 
murine model resulted in a reduction of scar tissue formation and increased nerve 
fibre regeneration (Atkins et al., 2008).  IL-10 may therefore have direct effects in 
peripheral nerves such as enhancing regeneration after injury and reducing 













1.3.5 Expression regulated by genotypes 
IL-10 production is reported to be influenced by the individual’s genotype with up 
to 75% of the variation in IL-10 levels due to gene promoter polymorphisms 
(Westendorp et al., 1997).  The IL-10 -1082A→G SNP (rs1800896, Entrez SNP 
Database) was shown to influence IL-10 transcription (Turner et al., 1997), with 
subjects homozygous for the G-allele producing almost double the amount of IL-10 
protein compared to those heterozygous or homozygous for the A-allele (Hoffmann 
et al., 2001).  This finding, however, is not consistent as other studies failed to prove 
an association between the G-allele and higher production of IL-10 (Lowe et al., 
2003).   
Currently there does not seem to be consensus in the literature on whether the G- 
or A-allele of the IL-10 -1082 SNP represents the ancestral allele. A number of 
studies reported the SNP to be a G-to-A substitution (Hoffmann et al., 2001, Lowe 
et al., 2003, Reichert et al., 2007), although the NCBI SNP database (Entrez SNP 
Database) showed an A-allelic frequency of greater than 50% in 86% of populations 
(all ethnicities combined) suggesting the A-allele to be the ancestral allele.  Limited 
data is available regarding allelic frequencies in African populations.  The G-allelic 
frequency in a Nigerian population has been reported as 31%, whereas between 
36% (Zabaleta et al., 2008) and 41% of African-Americans have this allele (Entrez 
SNP Database, Zabaleta et al., 2008).  
Two additional SNPs located downstream from the IL-10 promoter -1082 A→G SNP 
are the -819 C→T and the -592 C→A SNPs, which are both in linkage disequilibrium 
with the -1082 A→G SNP. The frequency of these alleles are marginally higher than 
the -1082 G-allele, with the -819 T-allele reported to have an frequency ranging 
from 36% to 54% in African-Americans, and the -592 A-allelic frequency ranging 
from 50% to 53% in the same population group (Entrez SNP Database). 
Three preferential haplotypes are formed, namely GCC, ACC and ATA (Hoffmann et 
al., 2001, Reichert et al., 2008) (Table 1.1).  The degree of functionality of these 
haplotypes seems to be solely dependent on the status of the IL-10 -1082 SNP.  












producers’, subjects heterozygous for the -1082 SNP ‘intermediate producers’ and 
subjects homozygous for the -1082 A-allele ‘low producers’, irrespective of the 
status of the -819C→T and -592C→A SNPs (Table 1.1) (Hoffmann et al., 2001). 
 
Table 1.1 IL-10 production based on haplotype  
High producers GCC/GCC 
Intermediate producers GCC/ACC 
GCC/ATA 
 ATA/ATA 
Low producers ACC/ATA 
 ACC/ACC 
 
1.3.6 IL-10 promoter SNP association studies 
Several studies have linked ‘high producer’ genotypes or haplotypes with the 
development of disease.  The ‘high producer’ GCC haplotype was associated with a 
higher risk of chronic airways infection with pseudomonas aeruginosa in subjects 
with cystic fibrosis (p=0.02) (Tesse et al., 2008).  The IL-10 -1082 G-allele was also 
shown to be significantly associated with the development of chronic hepatitis B 
infection (p=0.01) when compared to subjects who recovered from hepatitis B 
infection  (Truelove et al., 2008), and subjects with cervical cancer was more likely 
to have the -1082 G-allele (p=0.001) when compared to controls (Stanczuk et al., 
2001). 
The IL-10 -1082 A-allele was significantly higher in individuals with ulcerative colitis 
(p<0.001) compared to healthy controls (Tedde et al., 2008), and the -592 A-allele 
was associated with lower levels of IL-10 and higher rates of sepsis and mortality in 
critically ill patients (Lowe et al., 2003).  The abovementioned associations between 
the IL-10 promoter SNP and disease do not occur in a consistent manner, suggesting 
that IL-10 production is not exclusively dependent on the host’s genotype. 
Reports of the influence of IL-10 promoter polymorphisms on disorders of the 
nervous system are limited.  In subjects with Guillian-Barré, the -819CC and -592CC 












association was found with disease course (Myhr et al., 2003).  A recent report from 
an HIV-infected Zimbabwean cohort found an association between homozygous 
and heterozygous carriers of the -1082 G-allele and reduced mortality from 
HIV/AIDS as well as a reduction in the CD4 cell count depletion associated with the 
progression of HIV/AIDS, when compared to non-carriers of the G-allele (Erikstrup 
et al., 2007).  Although HIV-associated neuropathy is likely to correlate with both 
these parameters of disease severity, I was unable to find any reports investigating 
an association between IL-10 promoter polymorphisms and DSP. 
 
1.3.7 Hypothesis for cytokine promoter SNP association studies 
HIV infection results in a chronic state of immune activation.  The magnitude and 
pathogenic consequences of HIV-induced host inflammation may be influenced by 
functional cytokine gene polymorphisms.   We hypothesize that,  
1) as a pro-inflammatory cytokine, TNF-α promoter SNP A-alleles will be 
increased in subjects with painful HIV-associated DSP when compared to 
subjects without DSP, and  
2) as an anti-inflammatory cytokine, that IL-10 promoter “high producer” G-
alleles will be under-represented in those with painful HIV-associated DSP 
whereas the “low producer” haplotypes are more likely to occur in those 














Subjects and methods 
 
2.1 Ethical approval 
The study was approved by the Research Ethics Committee of the University of 
Cape Town (UCT) with references numbers UCT REC 227/2006 and UCT REC 
221/2008. 
 
2.2 Study population 
This study was conducted in collaboration with UCT’s Division of Endocrinology.  
Subjects were recruited from Crossroads Community Health Centre in Crossroads, 
Cape Town from August 2007 until October 2008.   This institution serves a 
predominantly isiXhosa-speaking community and runs a dedicated clinic for an 
estimated 5000 HIV-positive individuals. 
Study subjects were recruited from the clinic by a health care worker (myself and 
Dr. Joel Dave) and a trained field worker, who would also act as an interpreter 
between other study staff members and study participants if necessary.  After being 
counseled by the field workers, participants received an information leaflet and 
signed informed consent if they wished to participate.  Consent was given for study 
participation, blood sampling for biochemistry and storage of blood and DNA 
samples.  Clinic folders were briefly reviewed hereafter to screen for any obvious 
exclusion criteria (Table 2.1).  Subjects were then given an appointment date and 













Table 2.1: Exclusion criteria 
1. Age < 18 years 
2. Documented pre-existing neuropathy from a known cause 
3. Diagnosis of Diabetes Mellitus  
4. Current tuberculosis treatment for < 1 month 
5. ART for < 6 months 
6. Previously defaulting on ART 
7. Pregnancy 
8. Corticosteroid use in the past 6 months 
9. Acutely ill subjects 
10. Neurological signs not in keeping with a diagnosis of DSP (after examination) 
 
On the day of the appointment, subjects were escorted by a field worker from 
Crossroads clinic to Groote Schuur Hospital by public transport.  Participants were 
again informed about the procedure and the option to withdraw consent at any 
time if they were no longer interested.   
 
2.3 Blood and data collection 
Blood for a fasting lactate level was taken by finger prick without applying a 
tourniquet, where after IV cannulation was performed and blood taken for fasting 
glucose, insulin and lipid profile determinations, as well as DNA storage.  An 
Accutrend® Lactate system (Roche, Mannheim, Germany) was used for lactate 
samples.  A 75 gram oral glucose tolerance test (OGTT) was then performed, with 
blood taken for glucose and insulin measurements at 30 and 120 minutes.  Impaired 
fasting serum glucose was defined as a fasting glucose level of least 5.6 mmol/l, and 
impaired glucose tolerance was defined as a two-hour glucose level of at least 7.8 
mmol/l.  Diabetes was defined as a fasting glucose of at least 7 mmol/l or two-hour 
glucose level of at least 11.1mmol/l. 
All samples were collected in the appropriate Vacuette® (Greiner Bio-One, 












until the last samples were collected.  Digital blood pressure readings were 
recorded three times with the use of an Omron® M6 Comfort BP monitor (Omron 
Healthcare, Kyoto, Japan).  Data on weight, height and various other 
anthropometric measures were collected by the same investigator for all 
individuals, and field workers conducted interviews to complete questionnaires 
(Table 2.2).   
A South African validated, isiXhosa version of a health-related quality of life 
questionnaire with a 5-dimensional profile (EQ-5D) (Jelsma et al., 2004), was 
administered by trained field workers. The EQ-5D descriptive profile assesses health 
in terms of five dimensions; mobility, self care, activities of daily living (usual 
activities), pain or discomfort, and anxiety or depression.  Each dimension has three 
levels; no problems, some or moderate problems or severe problems.  For the 
purpose of analysis, responses were dichotomized as no problem vs. problems in 
each of the dimensions as the “severe” category was not always applicable to 
ambulatory subjects, and due to relatively few responses this category.  Subjects 
were also asked to rate their current health status on a 20cm long graduated visual 
analogue scale (VAS) ranging from the worst imaginable (0) to the best imaginable 
health (100%).  
 
Table 2.2: Information questionnaires 
1. Sociodemographic details 
2. Family history  
3. Previous medical history 
4. Current medication 
5. Exercise 
7. Tobacco and alcohol use 
8. Pregnancy history 













2.4 Long term storage 
After blood collection, tubes were spun down by technicians at 3000 rpm for ten 
minutes using a Beckman GS-6R centrifuge (GMI Inc., Ramsey, Minnesota, USA) and 
the contents of each aliquoted into 1,5 ml Eppendorf tubes, one of which was 
stored at -20˚C and the other stored in a -80˚C freezer for long-term storage.  All 
investigations were performed by the same laboratory technician. 
 
2.5 Examination for neuropathy 
The Brief Peripheral Neuropathy Screen (BPNS) and reduced Total Neuropathy 
Score (rTNS) are validated clinical tools used to document the presence of DSP.  
Both clinical tools require symptoms and signs to be symmetrically present, and 
subjects with asymmetry were excluded from analysis.  The majority of the clinical 
evaluations were performed by me and a minority by Prof. JM Heckmann.  On 
several occasions both examiners performed the tests independently with 100% 
concordance between the two raters.  A long-handled reflex hammer (Eschmann, 
England), 128 Hz tuning fork (RAGG, England) and solid-point pins were used for the 
determination of deep tendon reflexes, vibration sense and pin sensibility.   
 
2.5.1 Brief Peripheral Neuropathy Screen (BPNS) 
The BPNS (see Appendix A) grades symptom severity as well as vibration sense and 
ankle deep tendon reflexes.  A visual analogue scale (VAS) scoring each symptom 
from 0 to 10 is used by only explaining the extremes of the scale to the patient.  
Relevant symptoms consisted of the following: a) pain, aching or burning; b) pins-
and-needles and c) numbness experienced in the feet or lower legs.  After scoring 
on the VAS, symptoms were graded as being grade 1 (scores 1 – 3), grade 2 (scores 
4 – 6), grade 3 (scores 7 - 8) or grade 4 (scores 9 – 10).  The highest individual 












Vibration sense is evaluated by compressing or pinching the tuning fork hard 
enough for the ends of the arms to touch and applying it to the interphalangeal 
joint on the first toe of both feet, proximal to the nail bed.  Vibration loss is graded 
as none (> 10 seconds), mild (6 – 10 seconds), moderate (≤ 5 seconds) or severe (no 
vibration felt), and scored from 0 to 3 accordingly.  Ankle deep tendon reflexes are 
tested by sitting the patient over the bedside, relaxing the lower limbs and striking 
the tendon in the standard manner.  The reflexes and graded as being clonus, 
hyperactive, normal, hyporeflexia or areflexia, and scored from 0 to 4 accordingly.   
 
2.5.2 Reduced Total Neuropathy Score (rTNS) 
The TNS is a composite measure of peripheral nerve function developed by 
Cornblath et al. for the investigation of diabetic polyneuropathy (Cornblath et al., 
1999).  A reduced version of the TNS, only incorporating clinical assessment tools, 
was validated to be sensitive in the diagnosis of chemotherapy-induced peripheral 
neuropathy against established tools (Cavaletti et al., 2002, Cavaletti et al., 2003).  
We used a reduced version of the TNS (which we will refer to as the rTNS), which 
consists of 5 elements, namely symptoms (A), pin sensibility (B), vibration sensibility 
(C), deep tendon reflexes (D) and strength (E).  All 5 elements were graded from 0 
to 4 (see Appendix A).  For elements A to C, grades represented the level of 
involvement.  Reflex determination (D) was simultaneously graded according to 
severity and level of involvement.  Ankle- and toe plantar- and dorsiflexion (E) were 
only graded according to severity (Medical Research Council power grade). 
 
2.6 Criteria for a diagnosis of DSP 
As mentioned previously, no standard definition or reference standard for the 
investigation of DSP in epidemiological studies exists.  We did not have informative 
special investigations like quantitative sensory threshold testing (QST) or epidermal 












Neither the BPNS nor rTNS were considered to be adequate in isolation for a 
rigorous definition of DSP.  We used a combination of the BPNS and rTNS scoring 
methods as an evaluation tool to fulfill the recommended criteria for the definition 
as proposed by England et al. and to increase the sensitivity of our definition 
(England et al., 2005).  Both tools evaluate three different neuropathic symptoms, 
but the BPNS rates the symptoms on a VAS, and the rTNS includes the level of 
involvement.  The BPNS requires the presence of two signs, namely impaired 
vibration sense and hypo- or areflexia, and records the degree of impairment for 
either of these signs.  The rTNS grades a decrease in pin sensation in addition to the 
abovementioned BPNS signs, and grades the level of involvement rather than the 
degree of impairment.  However, for deep tendon reflexes both the level and the 
degree of impairment is incorporated into a single severity grade. 
To illustrate the difference in diagnostic sensitivity and specificity of the 2 clinical 
tools, Simpson et al. compared the original BPNS against the TNS, and subsequently 
revised the BPNS to require only 1 sign for the diagnosis of DSP (Simpson et al., 
2006).  As can be seen from the Table 2.3, marked differences in sensitivity and 
specificity were obtained.  When using only one abnormal sign for a diagnosis of 
DSP, the BPNS achieved a high rate of sensitivity and low rate of specificity when 
compared to the original TNS (which includes QST and sural- and peroneal nerve 
amplitudes).  Specificity improved markedly when increasing the abnormal signs 
needed to two, at the cost of sensitivity. 
 
Table 2.3. BPNS sensitivity and specificity compared to TNS (from Simpson et al., 2006) 
 Sensitivity (%) Specificity (%) Pos Pred Value Neg Pred Value 
BPNS (2 signs) 35 90 85 45 
BPNS (1 sign) 73 68 89 42 
Pos Pred Value = positive predictor value, Neg Pred Value = negative predictor value 
 
The BPNS was also compared to a reduced version of the TNS, which omitted 
quantitative sensory threshold testing and nerve conduction studies (Ellis et al., 












comparison to a reduced version TNS than it was compared to the TNS, but 
specificity was comparable (Table 2.4).  As expected, sensitivity increased and 
specificity decreased when only one sign was required for a diagnosis of DSP. 
 
Table 2.4. BPNS sensitivity and specificity compared to rTNS (from Ellis et al., 2005) 
 Sensitivity (%) Specificity (%) Pos Pred Value Neg Pred Value 
BPNS (2 signs) 49 88 53 85 
BPNS (1 sign) 80 59 72 69 (calculated) 
 Pos Pred Value = positive predictor value, Neg Pred Value = negative predictor value 
 
We decided to use a combination of the BPNS and rTNS, and base the diagnosis of 
DSP on the presence of at least 2 abnormal signs on clinical examination.  This 
implies that any combination of hypo-/areflexia, impaired vibration sense and 
decreased pinprick sensibility may be considered sufficient for the diagnosis.  With 
this definition we aimed to increase diagnostic sensitivity by examining for multiple 
sign, but also to increase specificity by requiring more than one to be present.  
Within group of subjects with DSP, symptom free subjects were classified as having 
asymptomatic DSP, and individuals with any grade of neuropathic symptoms were 
classified as having symptomatic DSP.   
 
2.7 Clinic folder reviews 
After testing, participants’ clinic records were reviewed by either me, Dr. Joel Dave 
or Prof. Jeannine Heckmann.  Descriptive data comprising the date of HIV diagnosis 
and WHO clinical stage on commencement of ART (if applicable) were collected.  In 
patients on ART, previous and current drug regimens with drug doses were 
recorded as well as any evidence of clinical ART toxicities or virological failure.  
Weight measurements were collected only on ART-exposed patients, and were 
tracked at designated intervals from the commencement of ART.   
Laboratory measures collected consisted of CD4 counts, HIV viral loads, mean 












Due to policy in the Western Cape Health region, viral load determination pre-ART 
initiation was discontinued as routine practice during 2007.  Consequently most 
individuals had their first viral load counts done after six months of ART and then at 
six-monthly intervals.  For ART-naïve subjects, CD4 counts within six months of the 
time of assessment were captured from clinic folders and regarded as nadir CD4 
count if no other value was available.  CD4 counts at the start of ART, six months 
thereafter as well as the most recent values (within 6 months of assessment) were 
recorded for ART-exposed subjects. 
 
2.8 Data capturing 
Data capturing was done by 2 different study staff members on 2 different 
workstations.  All datasets were entered into both Microsoft® Access databases, 
and compared afterwards for consistency.  Applicable data fields were exported to 
Microsoft® Excel prior to statistical analysis. 
 
2.9 Statistical analysis 
The primary analysis compared subjects without DSP to those with DSP, jointly 
evaluating individuals with HIV-DSP and those with ATN.  With this analysis we 
aimed to describe the prevalence of HIV-associated DSP and explore possible risk 
factors associated therewith.  To investigate potential risk factors for ATN, a 
secondary analysis was conducted to compare individuals with ATN to those who 
had been exposed to ART but had not developed ATN.  The cross-sectional nature of 
this study precluded evaluation of whether or not pre-existing HIV-DSP constitutes a 
risk factor for ATN.  Subject characteristics were compared using unpaired t-test, 
Wilcoxon rank-sum test, χ2 test, or Fisher exact test, as appropriate.  Risk factors for 
DSP in general as well as for ATN in particular were assessed using logistic 
regression.  Variables significant in univariate analyses at a 2-sided level of 0.05 
were evaluated in a multivariate model.  Interaction between variables significant in 












manipulation was done in Microsoft® Excel 2003, and statistical analyses were done 
in SPSS 16 (Chicago, Illinois, USA) and StatSoft® Statistica 8 (Tulsa, Oklahoma, USA).  
All analyses were supervised by a biostatistician, Dr. Motasim Badri, from the 














Laboratory materials and methods 
 
3.1 Study design 
We embarked on a pilot allele-association study, initially planning to genotype 30 
individuals with painful HIV-DSP and 30 individuals without evidence of HIV-DSP for 
the TNF-α promoter -308 G→A SNP, as well as the IL-10 promoter -1082 A→G SNP.  
The IL-10 promoter study was expanded during the course of the experiments to 
include the -819 C→T and -592 C→A SNPs as well, and will be discussed in detail 
below.  After conducting the TNF-α association study, we had excess reagents as 
well as eligible study participants, and decided to genotype additional subjects for 
the TNF-α -308 SNP.  The association study did not include participants on ART, as 
individuals with DSP included in this group can have HIV-DSP or ATN.  Samples for 
genotyping were numbered according to the clinical study number, and the 
personnel handling the samples were blinded to the clinical diagnosis of the 
participants. 
 
3.2 Subject selection for genotyping 
Subjects included in the TNF-α promoter -308 G→A genotype analysis and IL-10 
promoter haplotype analysis were selected by convenience sampling as this pilot 
study aimed to explore cytokine promoter gene differences in the extreme ends of 
the spectrum of DSP.  Neuropathy free subjects were compared to subjects with 
symptomatic HIV-DSP, as TNF-α has been implicated in the pathogenesis of painful 
neuropathy. 
A random selection of subjects with normal neurological examinations and without 
any symptoms of DSP were compared a group of subjects with symptomatic DSP, of 
which subjects with the highest BPNS- and rTNS scores were chosen.  The selected 












although a larger number of subjects were included in the TNF-α promoter analysis 
based on the expected allelic frequency of the -308 G→A SNP (see 3.1 Study 
design). 
 
3.3 DNA extraction and storage 
DNA extraction was performed from buffy coats prepared from Vacuette® 6ml 
EDTA tubes (Greiner Bio-One, Kremsmünster, Germany).  As mentioned earlier, 
tubes were centrifuged for ten minutes at 3000rpm using a Beckman GS-6R 
centrifuge (GMI Inc., Ramsey, Minnesota, USA) before buffy coats containing the 
white cells were aliquoted into 1.5ml Eppendorf tubes and stored at -20˚C in a long-
term storage facility.  A Qiagen QIAamp® DNA Blood Mini Kit (Valencia, California, 
USA) was used for the DNA extraction, and the standard Blood and Body Fluid Spin 
Protocol was followed.  The only alteration to the standard protocol was an 
increase in the incubation time after lysis from 10 minutes to an overnight 
incubation in an attempt to increase DNA yield.  DNA was subsequently stored at -
20˚C. 
 
3.4 Primers for polymerase chain reaction (PCR) 
All primers were designed using OLIGO® software (Molecular Biology Insights, Inc., 
Cascade, Colorado, USA) and manufactured locally by the Department of Molecular 
and Cell Biology, Synthetic DNA Unit, University of Cape Town.  In designing the 
primers we aimed for a length of 21 bases with minimal possibility of primer-dimer 
formation.  Primers used for TNF-α promoter and IL-10 promoter amplification are 













Table 3.1: TNF-α and IL-10 promoter PCR primers 
Primer Sequence Product size (bp) Tm (˚C)
δ
 
TNF-α -308 forward primer 5' aggcaataggttttgagggccat 3' 106 58.9 
TNF-α -308 reverse primer 5' cctccctgctccgattccg 3' 59 
IL-10 -1082 forward primer 5' caactggctccccttaccttc 3' 134 54 




3.5 Determination of annealing temperatures 
After DNA extraction, we established the optimal annealing temperatures for each 
of the primer sets by repeating PCR across a temperature gradient, using DNA from 
the same individual across all temperatures.  Primer stock was diluted to a 
50pmol/µl solution, and Promega GoTaq (Madison, Wisconsin, USA) was used in all 
experiments.   The PCR protocol (Table 3.2), temperature gradients (Table 3.3) and 




Table 3.3: Temperature gradients (˚C) 
TNF-α -308 53.3 56.7 58.4 59.9 61.8 
IL-10 -1082 50.3 51.9 54.9 56.7 58.4 
 
All gradient experiments were performed on an Eppendorf
®
 Mastercycler Gradient 
PCR system (Eppendorf, Hamburg, Germany).  A 2% agarose gel (Promega) was 
prepared, and 5µl (of a 10mg/ml solution) Bio-Rad
®
 ethidium bromide solution 
Table 3.2:  Protocol for annealing temperature gradient PCR 
Initialization 98˚C 2 minutes 
 
35 cycles 
Denaturation 94˚C 30 seconds 
Annealing gradient 30 seconds 
Elongation 72˚C 30 seconds 












(Hercules, California, USA) was added during the preparation.   During heat 
dissolving of the agarose, evaporation losses were replaced with distilled water.  
15µl of 1kb+ DNA ladder (SolGent, Daejeon, South Korea) was added to one lane as 
a reference, and the gel was run for 30 minutes at 110V.  Good results across most 
temperatures were seen for TNF-α promoter amplicon and a well-defined band at 
58.4˚C for the IL-10 promoter (Figure 3.1).  It was decided to use an annealing 
temperature of 58˚C for both cytokines. 
 
 
Figure 3.1: Cytokine promoter annealing temperature determination. A) TNF-α annealing 
temperature determination gel; B) IL-10 annealing temperature determination gel. 
 
3.6 Polymerase Chain Reaction 
For both cytokines, a 30µl PCR sample from each subject was prepared to minimise 
cost but still allow for a checking gel to be performed verifying the quality of the 
PCR product.  Of the 30µl, 12µl of PCR product would be used for the checking gel, 




















The PCR protocol used was similar to that described earlier, with the annealing step 
set at 58˚C (Table 3.5).  All reactions were performed on either an Eppendorf® 
Mastercycler Gradient PCR system or GeneAmp® 2700 PCR system (Applied 
Biosystems, Singapore).  A control sample was prepared with every group of 
samples, with nuclease-free water replacing subject DNA.  This was done to exclude 
any contamination with amplicons or extracted DNA.  A known negative- and 
positive control (from a previous study by Prof JM Heckmann) were also amplified 





After PCR, checking gels were run to confirm adequate amplification of the PCR 
product prior to restriction enzyme digestion (figure 3.2).  All checking gels used 
were 2% (w/v) agarose gels, and underwent electrophoresis at 110V for 45 minutes.  
None of the checking gels showed any contamination during any of the 
experiments.  All photographs were taken with a Kodak DC120 digital camera and 
Table 3.4: PCR reagent volumes 
Reagent (concentration) Volume (µl) 
Forward Primer (50pmol/µl ) 0.3 
Reverse Primer (50pmol/µl ) 0.3 
dNTPs (5mM) 1.2 
5X Taq Buffer 6 
MgCl (25mM) 18 
Distilled water 19.26 
Promega GoTaq 0.14 
Subject DNA 1 
Total volume 30 
Table 3.5: Cytokine promoter PCR protocol 
Initialization 98˚C 2 minutes 
 
35 cycles 
Denaturation 94˚C 30 seconds 
Annealing 58˚C 30 seconds 
Elongation 72˚C 30 seconds 












Kodak 1D Image Analysis software (Rochester, New York, USA) under UV 
transillumination on a Stratagene® Transilluminator 4000 (La Jolla, California, USA). 
 
Figure 3.2: Example of a TNF-α PCR product checking gel. 
 
3.7 TNF-α promoter genotyping by NcoI restriction 
NcoI restriction enzyme digestion for TNF-α promoter -308 genotyping was first 
described in 1992 (Wilson et al., 1992).  The NcoI restriction enzyme recognises the 




A mismatch primer with a single base change at the 3' end of the primer was 
necessary to create an NcoI restriction site.  As indicated in the sequence below 
(Figure 3.3), the enzyme digests the ancestral (GG) genotype, cleaving the 106bp 
amplicon in a 20bp fragment and an 86bp fragment.  PCR products of subjects 
homozygous for the TNF-α promoter -308 G→A SNP will therefore not be digested 
and only show a 106bp strand on gel electrophoresis, whereas heterozygotes will 




























Figure 3.3: TNF-α promoter sequence.  Highlighting denotes the forward- and reverse primer, with 
the red base denoting the mismatch created by the forward primer.  Underlying denotes the TNF-α -
308 SNP.  Blue type denotes the start of the TNF-α gene. 
 
The NcoI enzyme (R0193S) was supplied by New England Biolabs (Ipswitch, 
Massachusetts, USA), together with NEBuffer 3 that allows 100% activity of the 
enzyme.  Final reaction volumes for enzyme digestion are shown in Table 3.6.  
Enzyme digestion was performed overnight (16 hours) on a GeneAmp® 2700 PCR 
system at 37˚C as per manufacturer’s instructions.  An overnight digestion was 






Table 3.6: NcoI enzyme digestion volumes 
Reagent  Volume (µl) 
PCR product 18 
NcoI enzyme 0.2 
NEBuffer 3 2 
Total volume 20.2 
Forward primer 















                                 
Figure 3.4: NcoI restriction enzyme digestion test 
 
3.8 IL-10 genotyping by MnlI restriction 
MnlI restriction enzyme digestion for IL-10 promoter -1082 genotyping was first 
described in 2001 (Zheng et al., 2001).  The MnlI nzyme recognises the sequence 
GGAG on the reverse strand of the promoter.  In subjects with the ancestral (AA) 
genotype, the amplified DNA fragment (134bp) contains one restriction site in the 3' 
end of the fragment (see below).  The IL-10 promoter -1082 A→G polymorphism 
creates a second restriction site, and expected fragments from the different 





Table 3.7: IL-10 promoter -1082 base pair lengths 
Genotype Number of fragments Base pair lengths 
AA 2 114, 20 
GG 3 91, 23, 20 











































       Figure 3.5: IL-10 promoter sequence.  Highlighting denotes the forward- and reverse primer.     
       Underlying denotes the polymorphism site.  Blue type denotes start of the IL-10 gene. 
 
PCR conditions, equipment and gel concentrations were the same as for TNF-α -308 
genotyping.  The MnlI enzyme (R0163S) was supplied by New England Biolabs, 
together with Bovine Serum Albumin (BSA) and NEBuffer 2 that allows 100% activity 
of the enzyme.  Final reaction volumes for enzyme digestion are shown in Table 3.8.  
Enzyme digestion was also performed overnight at 37˚C, with a final enzyme-
inactivation step at 65˚C for 20 minutes. 
Forward primer 






























3.9 Gel electrophoresis of enzyme-restricted products 
The TNF-α -308 genotype determination relies on the detection of either a 106 bp 
or an 86 bp fragment on gel electrophoresis, and IL-10 -1082 determination on 
either a 114 bp or 91 bp fragment.  For better separation of the similarly-sized 
bands, we used 4% (w/v) agarose gels with a length of 15cm (110ml).  The volume 
of ethidium bromide (of a 10mg/ml solution) was increased to 7.5µl for larger gels.  
15µl of Low Molecular Weight DNA Ladder (N3233S) (New England Biolabs, 
Ipswitch, Massachusetts) were used, and undigested PCR product was always added 
to the outermost lanes of the gel as reference points. 
 
3.10 IL-10 promoter sequencing 
No conclusive results for the majority of subjects could be obtained by MnlI enzyme 
restriction (Figure 3.6).  Bands of various sizes were seen on gel electrophoresis, and 
this is believed to have been caused by a CA-repeat section in the 5' end of the 
amplified fragment of the promoter gene.  This section spans 42 bases, and 
misreads in this area could explain the observed minor variation in base pair length. 
Table 3.8: MnlI enzyme restriction volumes 
Reagent Volume (µl) 
PCR product 18 
MnlI enzyme 0.4 
NEBuffer 2 2 
BSA 0.2 













Figure 3.6: MnlI restriction enzyme digestion of IL-10 promoter -1082 SNP. Various band sizes are 
seen apart from the expected fragment sizes mentioned in table 3.7.  * denotes undigested control 
samples. 
 
It was decided to sequence the IL-10 promoter area instead.  This gave rise to the 
opportunity to expand the amplified segment and include 2 other SNPs in the 
promoter gene that have been implicated in altered expression of the cytokine (see 
1.3.5 Expression regulated by genotypes). 
 
3.10.1 Primer design 
The previously designed forward primer was used for sequencing, and 2 new 
reverse primers were designed.  Reverse sequencing was done to avoid possible 
problems arising from the CA-repeat section, and the 2
nd
 reverse primer was used 
for internal sequencing as this resulted in better sequencing compared to the 














Table 3.9: IL-10 promoter -1082 PCR primers for sequencing 
Primer Sequence Product (bp) Tm (˚C) 
IL-10 -1082 forward primer 5' caactggctccccttaccttc 3'  54 
IL-10 -1082 reverse primer 5' cagtgacgtggacaaattgcc 3' 816 55 
































       Figure 3.7: IL-10 promoter sequence.  Highlighting denotes the forward- and 2 reverse primers.   









Reverse primer 2 
 



















3.10.2 PCR for IL-10 promoter sequencing 
PCR conditions were similar to those described in section 3.6.  Annealing 
temperature determination by use of a gradient experiment was again done, with 
the only alteration to the protocol being an increase in elongation step due to the 
increased size of the amplified fragment (Table 3.10 and Table 3.11).  An annealing 
temperature of 58˚C resulted in a well defined band on gel electrophoresis, and was 






Table 3.11: Temperature gradients (˚C) 
IL-10 -1082 51.9 54.9 56.7 58.4 59.9 
 
                        
           Figure 3.8: IL-10 promoter sequencing annealing temperature gel. 
Table 3.10: PCR protocol for IL-10 sequencing 
Initialization 98˚C 2 minutes 
 
35 cycles 
Denaturation 94˚C 30 seconds 
Annealing gradient 30 seconds 
Elongation 72˚C 60 seconds 












3.10.3 Purification of PCR product 
PCR products were purified using QIAquick® PCR Purification Kit (Qiagen, Valencia, 
California, USA) and the standard PCR Purification Spin Protocol. 
 
3.10.4 Measuring of DNA concentrations 
DNA concentration of all 60 samples were measured and was done by aliquoting 2 
µl of purified DNA onto a NanoDrop® ND-1000 Spectrophotometer.  Prior to 
measuring concentrations, the device was calibrated using a sample of nuclease 
free water followed by a sample of elution buffer.  DNA concentrations were all 
satisfactory for sequencing and varied between 18.4ng/µl and 73.5ng/µl. 
 
3.10.5 Sequencing protocol 
Sequencing reactions were performed using a BigDye® Terminator Cycle Sequencing 
Kit (Applied Biosystems, Foster City, California, USA).  Reaction volumes and 
sequencing protocol are listed in Table 3.12 and Table 3.13.  Samples were 
sequenced by the Central DNA Sequencer, University of Stellenbosch and were 





Table 3.12: Sequencing reagent volumes 
Reagent Volume (µl) 




Purified PCR product 1 




















Table 3.13: Sequencing reaction protocol 
Initialization 96˚C 15 seconds 
 
30 cycles 
Denaturation 96˚C 15 seconds 
Annealing 50˚C 30 seconds 
Elongation 60˚C 4 minutes 
















4.1 Study participants 
Informed consent was granted by 640 individuals, after which 42 individuals were 
excluded due to reasons listed in Table 4.1.  The remaining 598 individuals were 
included in the analysis. 
 
Table 4.1: Excluded subjects 
Subjects (N) Reason 
12 Withdrawn consent 
10 Unsuccessful IV cannulation after two attempts 
6 Corticosteroid use in the past six months 
4 Inadequate duration of ART exposure 
4 Pregnancy 
4 Incomplete data capturing 
1 Brown-Sequard syndrome 
1 Possible neuropathy due to rheumatoid arthritis 
42  
 
4.2 DSP prevale ce 
The overall prevalence of DSP (as defined by our clinical definition) in this 
population was 49% (n=291), and approximately two-thirds (180/291) of subjects in 
this group suffered from symptomatic DSP (Table 4.2).   
The prevalence of DSP changes significantly with a change in definition.  Using a 
definition that requires only 1 sign for a diagnosis of DSP as used by several 
previously published studies (Wright et al., 2008, Sithinamsuwan et al., 2008) 
increases the DSP prevalence to 80% (477/498) (p<0.0001 compared to a definition 
including 2 signs).  Participants with symptomatic DSP accounts for 42% of the 












proportion (224/477, 47%) of all subjects with DSP are categorized as having 
asymptomatic DSP when using this definition, compared to a definition requiring 2 
signs for the diagnosis of DSP (111/291, 38%) (p=0.017). 
 
Table 4.2: DSP prevalence 
  N,% 
No DSP  307 (51.3) 
DSP 291 (48.7) 
Asymptomatic DSP 111 (18.6) 
Symptomatic DSP 180 (30.1) 
Total  598 (100) 
 
 
4.3 Data on symptoms and signs 
Data regarding symptom and sign frequency is presented in Table 4.3.  All the 
symptoms and signs included in the definition of DSP were significantly more 
prevalent in the DSP subgroup compared to the DSP-free subgroup.  Within the 
symptomatic DSP subgroup, 69% of subjects (125/180) reported positive sensory 
symptoms (pain or paresthesiae) graded as being at least moderate to severe 
(≥4/10) on the BPNS symptom VAS.  Pain was the most prevalent DSP symptom, 
affecting nearly half of all subjects with DSP (47%), but also present in 24% of 
individuals without DSP.  Cramps as a neuropathic symptom were more prevalent in 
participants with DSP, although reported by 37% of those without DSP. 
On the BPNS VAS, 278 study participants reported symptoms, although only 180 of 
these had DSP according to our definition.  Of the remaining 98 subjects, 73 had 1 
abnormal sign on examination, and 25 participants did not have any abnormalities. 
On retrospective recall, 17% (30/180) of individuals with symptomatic DSP reported 
relief from various preparations (apart from ART), most often ascribed to the use of 
either paracetamol or amitriptyline, but also including physical measures such as 












Hypo- or areflexia was the commonest sign in individuals with DSP, affecting 86% of 
the group, but also affecting 31% of individuals without DSP.  The second most 
common sign in our study population but absent in the BPNS tool, decreased 
pinprick sensation, was present in 85% of subjects who were classified as having 
DSP and abnormal in 20% of individuals without DSP.   
Table 4.3: Symptom and sign-frequency in the cohort stratified by DSP status 
  No DSP DSP p-value 
  N = 307 N = 291  
Neuropathic symptoms     
Pain N (%) 74 (24.1) 136 (46.7) <0.001
 ε
 
Paresthesiae N (%) 49 (16) 109 (37.5) <0.001
 ε
 
Numbness N (%) 29 (9.4) 90 (30.9) <0.001
 ε
 
Cramps N (%) 113 (36.8) 160 (55) <0.001
 ε
 
Neuropathic signs     
Hypo-/areflexia N (%) 94 (30.6) 251 (86.3) <0.001
 ε
 
Vibration loss N (%) 32 (10.4) 196 (67.4) <0.001
 ε
 








4.4 Risk factors for Distal Sensory Polyneuropathy 
Subjects with DSP were older compared to those without DSP (p<0.001), and more 
likely to have been exposed to ART (p<0.001) or previously treated TB infection 
(p<0.001) (Table 4.4 and 4.5).  Both current stavudine use (p=0.002) and stavudine 
use ever (p<0.001) were more prevalent in the DSP-group, but neither duration of 
use in currently-exposed subjects, nor duration of use in all subjects who had used 
stavudine was different from that of the DSP-free group (p=0.79).   
With regards to laboratory markers, individuals with DSP had lower nadir CD4+ 
counts (p<0.001) and higher current mean corpuscular volumes (MCV) compared to 
those without DSP (p=0.01). The relevance of this finding is unclear, but the 
observed macrocytosis in the DSP-group may be related to the higher rate of ART 
use in this group. Total fasting cholesterol levels were significantly higher in the DSP 
group (p=0.007), although the values of the 75
th
 percentile of both groups was still 
within the normal range.  No differences in either fasting serum glucose levels, two-












No difference was detected in smoking habits or alcohol exposure in general, 
although an insignificant trend towards increased alcohol use in the past 12 months 
was observed in DSP-free subjects (p=0.08).  Significant differences were 
demonstrated in weight (p=0.043), waist-to-hip ratio (p<0.001) and both systolic- 
and diastolic blood pressure measurements (p<0.001 and p=0.019, respectively) 
between DSP and DSP-free groups, although the values of the 75
th
 percentiles for 
systolic and diastolic measurements were within the normal range.  No significant 
differences in height, body mass index, mid-upper arm circumference or calf skin 
fold thickness were demonstrated.  Measured across both DSP and DSP-free groups, 
3% of study participants were underweight with a BMI < 19, whereas 73% of 
subjects had a BMI of greater than 25.  Out of 568 subjects, 141 (25%) were 
classified as being morbidly obese (BMI ≥ 35). 
 
Table 4.4: Demographic, clinical and laboratory characteristics of the cohort stratified by 
                   DSP status 
  No DSP DSP p- 
 
¤
 N = 307 N = 291 value 
Age Median (IQR) 32 (27.5 - 37) 35 (30 - 43) <0.001
 β
 
Female N (%) 239 (77.9) 223 (76.6) 0.72
 ε
 
Systolic blood pressure Median (IQR) 103.8 ( 94.7- 114.3) 109.7 (99.3 - 119.8) <0.001
 β
 
Diastolic blood pressure Median (IQR) 69.8 ( 60.7 - 78.3) 71.5 (62.7 - 80) 0.019
 β
 
Weight (kilograms) Median (IQR) 64.5 (55.7 - 75.2) 67.0 (57.0- 80.3) 0.043
 β
 
Height (meters) Median (IQR) 1.49 (1.43 - 1.56) 1.50 (1.42 - 1.58) 0.10
 β
 
Body Mass Index Median (IQR) 29.1 (24.4 - 34.4) 29.7 (25 - 35.5) 0.15
 β
 





 (cm) Median (IQR) 27.5 (25 - 30.5) 28 (15 - 31) 0.37
 β
 





 N (%) 67 (29.5) 65 (30.8) 0.77
 ε
 
CD4 nadir count 
 








Median (IQR) 102.4 (92.3 - 109.8) 107.05 (99.6 - 113.8) 0.01
 β
 
 Fasting lactate Median (IQR) 1.9 (1.3 - 2.4) 1.7 (1.25 - 2.4) 0.25
 β
 




IQR = interquartile range 
β






 Abnormal glucose metabolism includes diabetic and pre-diabetic state  
γ
 Mid-upper arm circumference 
κ














Table 4.5: Additional risk factors for DSP and treatment use of the cohort stratified by DSP status 
  No DSP DSP p-value 
 
¤ 
N = 307 N = 291  
Alcohol exposure ever N (%) 151 (49.2) 134 (46) 0.44
 ε
 
Alcohol exposure in 12 months N (%) 105 (34.3) 80 (27.6) 0.08
 ε
 
Smokers currently N (%) 46 (15) 51 (17.5) 0.40
 ε
 
Daily smokers N (%) 38 (12.4) 39 (13.4) 0.71
 ε
 
Previous TB N (%) 119 (38.8) 162 (55.7) <0.001
 ε
 
Current TB N (%) 10 (3.3) 12 (4.1) 0.57
 ε
 
Current Vit B complex use  N (%) 280 (91.2) 259 (89) 0.22
 ε
 
Current ART exposure N (%) 99 (32.2) 168 (57.7) <0.001
 ε
 
Current d4T use 
δ
 N (%) 71 (23.3) 100 (36.5) 0.002
 ε
 
d4T use ever N (%) 87 (28.5) 130 (47.4) <0.001
 ε
 
d4T (ever) duration (months) Median (IQR) 13.0 (8-20) 14.0 (8-20) 0.79
 β
 
d4T current duration (months) Median (IQR) 13 (8 – 20) 14 (8 – 20) 0.53
 β
 




IQR = interquartile range 
β






 d4T and stavudine are used interchangeably 
 
4.4.1 Logistic regression for the cohort, stratified by neuropathy status (DSP versus 
no DSP) 
Individual univariate logistic regression analyses were conducted to determine risk 
factors associated with DSP.  All variables were explored for an association with 
DSP, but only variables showing a significant association are presented in Table 4.6.  
Several potential risk factors identified by non-parametric and proportional analyses 
(Table 4.4 and Table 4.5), such as weight and blood pressure measurements, failed 
















Table 4.6: Univariate logistic regression for factors associated with DSP 
 Odds Ratio (95% Confidence p-value 
Age (per 10-year increase) 1.06 (1.04 - 1.08) <0.001 
ART use   <0.001 
Yes 2.87 (2.06 - 4.01)  
No 1   
CD4 count < 200 cells/μl   <0.001 
Yes 2.38 (1.62 – 3.51)  
No 1   
Previous TB infection   <0.001 
Yes 2.48 (1.75 - 3.50)  
No 1   
 
We then proceeded to a multivariate logistic regression analysis to identify factors 
independently associated with a risk of developing DSP.  Only variables that showed 
significance in the univariate analyses were included in the multivariate model, and 
the results presented in Table 4.7.   
CD4 count failed to show an independent association with DSP, although age (per 
10-year increments), ART use and previously treated TB infection remained 
independently associated with risk of developing DSP. 
 
Table 4.7: Multivariate logistic regression for factors independently associated 
 Odds Ratio (95% Confidence p-value 
Age (per 10-year increase) 1.72 (1.35 – 2.20) <0.001 
ART use   0.04 
Yes 1.71 (1.03 – 2.85)  
No 1   
CD4 count < 200 cells/μl   0.31 
Yes 1.32 (0.78 – 2.24)  
No 1   
Previous TB infection   0.002 
Yes 1.97 (1.28 - 3.04)  












4.5 Asymptomatic and Symptomatic DSP 
An analysis was performed on the asymptomatic DSP and symptomatic DSP 
subgroups to determine whether any potential risk factors significantly associated 
with either of the groups.  Individuals with symptomatic DSP were older than those 
with asymptomatic DSP (p=0.007) but symptomatic DSP did not associate 
significantly with any other risk factors, including alcohol use, previous TB infection, 
ART use or markers of impaired glucose metabolism (Table 4.8).  
Of the 111 subjects currently with asymptomatic DSP, 30 (27%) reported having 
experienced HIV-related neuropathic symptoms in the past and most of these 
(25/30) are currently in the ART-exposed group.  Of the latter 25 ART-exposed 
individuals currently with asymptomatic DSP, 21 (84%) reported resolution of 
symptoms after initiating ART, suggesting that ART may have a beneficial impact on 
patients with symptomatic HIV-DSP. 
 
Table 4.8: Asymptomatic vs. Symptomatic DSP 
  Asymptomatic DSP Symptomatic DSP p-value 
 
¤
 N = 111 N = 180  
Age Median (IQR) 33 (29 -39) 36 (31 – 44) 0.007 
β
 
Female N (%) 84 (75.7) 139 (77.2) 0.76
 ε
 
Alcohol past 12 months N (%) 34 (30.6) 46 (25.7) 0.36
 ε
 
Previous TB N (%) 57 (60.0) 105 (65.2) 0.40
 ε
 
ART exposure N (%) 63 (56.8) 105 (58.3) 0.79
 ε
 
D4T use (current) N (%) 37 (34.9) 63 (37.5) 0.66
 ε
 
D4T use (ever) N (%) 52 (49.1) 78 (46.4) 0.67
 ε
 
D4T duration Median (IQR) 14 (8 – 22) 14 (8-20) 0.88
 β
 
AZT use N (%) 21 (36) 31 (33) 0.72 
ε
 
Height (meters) Median (IQR) 1.52 (1.42 – 1.59) 1.48 (1.43 – 1.57) 0.31
 β
 
Waist-to-Hip ratio Median (IQR) 0.86 (0.81 – 0.92) 0.87 (0.83 – 0.92) 0.31
 β
 
CD4 nadir Median (IQR) 153 (78 – 237) 144 (73 – 203) 0.74
 β
 
CD4 current Median (IQR) 342 (212 – 499) 300 (183 – 433) 0.16
 β
 
Impaired glucose N (%) 27 (33.8) 38 (29) 0.47
 ε
 









IQR = interquartile range 
β



















4.6 Impact of ART on DSP 
The prevalence of DSP in both the ART-naïve and ART-exposed subgroups are 
shown in Table 4.9.  DSP developing in ART-naïve subjects is related to the effects of 
HIV-infection (HIV-DSP) whereas DSP in the ART-exposed group may be due to ART-
related toxic neuropathy (ATN) as well as HIV-DSP.  For the purposes of this 
discussion the latter group will be referred to as ATN with the understanding that in 
a cross-sectional analysis this definition is not entirely accurate. 
Overall, DSP prevalence was significantly higher in the ART-exposed subgroup (63%) 
compared to the ART-naïve subgroup (37%, p<0.001).  Furthermore, 23% of those 
with HIV-DSP had symptomatic DSP whereas 39% of the ATN group could be 
classified as symptomatic DSP.  Similarly, asymptomatic DSP was also more 
prevalent amongst those with ATN (HIV-DSP 15% vs. ATN 24%).  Of those with 
symptomatic ATN, 42% retrospectively recalled symptom onset within two to four 
months of initiating ART.  Conversely, symptom relief (but not resolution) from ART 
was reported by 31% (32/105) of ART-exposed individuals. 
The neuropathic symptoms of pain, paresthesiae and numbness, as expressed as a 
VAS-interval grading scale (0 to 4) (see Appendix A) showed a trend towards higher 
scores in the HIV-DSP group compared to those with ATN (p=0.037).  However, the 
rTNS scores were significantly worse in the ATN group (HIV-DSP mean 3.1, SD±2.8; 
ATN mean 4.6, SD±3.2; p<0.001).  
 
Table 4.9: DSP prevalence, stratified by ART exposure 
  Cohort (N, %) ART-naïve (N, %) ART-exposed (N, 
No DSP  307 (51.3) 208 (62.8) 99 (37.1) 
DSP 291 (48.7) 123 (37.2) 168 (62.9) 
Asymptomatic DSP 111 (18.6) 48 (14.5) 63 (23.6) 
Symptomatic DSP 180 (30.1) 75 (22.7) 105 (39.3) 














Consistent with the analysis of the entire study population, age was higher 
(p<0.001) and previously treated TB infection more prevalent (p=0.02) amongst 
those with ATN compared to those without (Table 4.10).  Interestingly, the median 
increase in MCV from ART initiation to follow-up at 6 months was also higher in 
subjects with ATN (p=0.041) compared to those on ART without ATN.  
There was no observable difference in the proportion of participants who have ever 
been exposed to stavudine in the ATN group compared to those without ATN 
(p=0.33).  There was, however, a difference between the two groups when 
evaluating current d4T use; a significantly lower proportion of subjects with ATN 














Table 4.10: Demographic, clinical and laboratory characteristics of ART-exposed subjects with (ATN) 
                     and without DSP 




 N = 99 N = 168  
Age Median (IQR) 32 (28 - 37) 36 (31 - 44) <0.001
 β
 
d4T exposure ever N (%) 87 (89.7) 129 (85.4) 0.33
 ε
 
 Current d4T exposure N (%) 71 (71.1) 100 (59.5) 0.045
 ε
 
No d4T ever N (%)  10 (10.3) 22 (14.6) 0.33
ε
 
D4T duration Median (IQR) 13.0 (8-19) 16.5 (8-24) 0.22
 β
 
Previous TB N (%) 63 (63.4) 130 (77.6) 0.018
 ε
 
 Current TB N (%) 0 (0) 2 (1.2) 0.28
 ε
 
Current vit B Complex use N (%) 92 (92.9) 143 (85.1) 0.06
 ε
 
 Alcohol past 12 months N (%) 30 (30.3) 35 (20.8) 0.08
 ε
 
Daily smokers N (%) 7 (7.1) 20 (11.9) 0.21
 ε
 
BMI Median (IQR) 31.0 (24.9-35) 30.2 (24.9-35.4) 0.96
 β
 
Weight (current) Median (IQR) 65.3 (59.5 - 77.3) 68.0 (57.3 - 79.7) 0.37
 β
 
 Weight increase in 3 months Median (IQR) 4.0 (0.5 - 6.6) 2.5 (0 - 5.5) 0.15
 β
 
Weight increase in 6 months Median (IQR) 4.1 (1.6 - 9.2) 4.9 (0.7 – 8.1) 0.64
 β
 












 change from baseline Median (IQR) 18.5 (13.3 - 24.9) 21.3 (16.5 - 26.6) 0.041
 β
 
Fasting cholesterol Median (IQR) 4.23 (3.45 - 4.81) 4.46 (3.83 - 5.3) 0.12
 β
 
 Fasting lactate (mmol/l) Median (IQR) 1.9 (1.3-2.4) 1.7 (1.3-2.4) 0.46
 β
 
Impaired glucose  N (%) 35 (35.8)  57 (34.1) 0.80
 ε
 
CD4 nadir count 
 
Median (IQR) 125 (74 - 155) 108 (47 - 160) 0.12
 β
 
 CD4 start Median (IQR) 132 (78 - 164) 111 (49 - 165) 0.013
 β
 









IQR = interquartile range 
β






 Mean corpuscular volume.  Change from baseline is defined as the difference between pre-ART 
measurement and that at 6 months of ART-exposure 
*
 Defined as an increase in CD4+ count of > 50 cells/μl between pre-ART and 6-months post-ART 
values 
 
We did not show a difference in nadir CD4 count values between subjects with ATN 
and those without.  In ART-exposed individuals the CD4 count value recorded prior 
to ART initiation represented “CD4 start”, and was marginally higher than nadir 
values in both the ATN and ATN-free groups. It was also significantly higher in 












The definition of the immune reconstitution syndrome requires the clinical 
syndrome to co-occur with evidence of immune recovery on ART initiation 
(Dhasmana et al., 2008).  The relationship between ATN and immune reconstitution 
was evaluated by assessing the presence of ATN with the change in CD4 count from 
the pre-ART measurement to that at six months on ART.  We arbitrarily defined 
immune reconstitution as an increase in CD4 count of at least 50 cells/µl as a 
positive result, but no association with ATN was demonstrated.   Viral load counts 
were available for less than a quarter of ART-exposed individuals at baseline, and 
were therefore not used in the definition of immune reconstitution. There was also 
no significant association demonstrated between other measures specific to ART-
exposed participants, such as an increase in body weight after three- and six-
months of exposure to ART, and ATN.   
Risk factors significantly associated with ATN in the previous analysis (non-
parametric and proportional; see Table 4.10) were also examined by individual 
logistic regression to confirm significance prior to being included in the multivariate 
model (Table 4.11).  Age (per 10-year increments), a history of previously treated TB 
infection and median increase in MCV (in the first 6 months) of ART, all remained 
independently associated with ATN in the multivariate model. 
 
Table 4.11: Logistic regression for factors associated with ATN 
 Univariate analysis Multivariate analysis 
 OR (95% CI)
 β
 p-value OR (95% CI)
 β
 p-value 
Age (per 10-year 1.07 (1.03 – 1.10) <0.001 1.92 (1.20 – 3.07) 0.006 
Previous TB infection  0.018  0.015 
Yes 1.99 (1.12 – 3.53)  2.99 (1.24 – 7.22)  
No 1  1  
MCV increase on ART
*
 1.05 (1.01 – 1.10) 0.02 1.06 (1.01 – 1.11) 0.03 
β
 OR = Odds Ratio, CI = confidence Interval 
*













4.7 Adherence to ART regimens  
Adherence to ART regimens as reported by the subjects was excellent; only three 
subjects reported inadvertently missing one to three days of dosing.  Six-monthly 
viral load assessments post treatment initiation were available from folder reviews 
(N=156) and was lower than the detectable limit (<50 IU/ml) in 85% of subjects, 
although only 45 of these subjects had pre-ART viral load values. 
 
4.8 Quality-Of-Life assessment  
Results of the EQ-5D questionnaire are presented in Table 4.12.  Within the DSP 
group, there was a significantly higher proportion of individuals who reported 
impaired mobility compared to those without neuropathy (p=0.005).  No significant 
differences were noted in any of the other dimensions, nor in the EQ-5D VAS on 
current state of health (expressed as a percentage). The dimensions of 
pain/discomfort and anxiety/depression were most frequently reported as 
abnormal and often in similar proportions whether there were associated DSP or 
not. 
 
Table 4.12: Proportion of affected individuals in the dimensions of the EQ-5D 
 No DSP DSP p-value 
 N (%) N (%)  
Mobility 10 (3.3) 25 (8.6) 0.005
 ε
 
Self-care 2 (0.7) 3 (1.0) 0.61
 ε
 










 42 (13.7) 42 (14.4) 0.79
 ε
 
EQ-5D Health today VAS 
(%) 
80 (70 – 90)
 ¤






median (interquartile range) 
β






 “pain” refers to pain or discomfort 
#













In order to evaluate the influence of ART on the response of participants in each of 
the dimensions of the EQ-5D, each category was stratified by ART use and results 
are presented in Figure 4.1.  Amongst the ART-naïve subjects, a higher proportion of 
subjects with HIV-DSP (blue bars) reported impaired mobility compared to those 
without DSP (green bars) (14% vs. 5%, p=0.004).  The proportion of individuals with 
HIV-DSP who reported impaired mobility were also significantly higher than that of 
participants with ATN (14% vs. 5 %, p=0.01).  In the ART-naïve subgroup those with 
DSP reported pain or discomfort more frequently than individuals without DSP (32% 
vs. 23%, p=0.07).  Although not significant there was a tendency towards a lower 
proportion with pain or discomfort experienced by those with ATN compared to 
those with HIV-DSP (ATN 23% vs. HIV-DSP 32%, p=0.08).  From the figure it can also 
be seen that subjective impairment reported by individuals with ATN was 
comparatively lower than that reported by participants with HIV-DSP across all 5 
dimensions of the EQ-5D. 
 
 
Figure 4.1: EQ-5D results, stratified by diagnostic groups and ART status.  ART-n = ART-naïve, ART-e 


















5.1 TNF-α promoter -308G→A SNP 
As mentioned in earlier (see 3.9 Gel electrophoresis of enzyme-restricted products), 
NcoI enzyme restriction cleaves the amplified 106bp PCR product in 20bp and 86bp 
fragments in subjects with the ancestral genotype, whereas it does not digest the 
PCR product of subjects with the SNP.  Recognition of the genotype is based on the 
difference between 86bp and 106bp fragments, and a DNA ladder with markers in 
25bp increments was chosen to differentiate between the expected band sizes.  The 
gel sample (Figure 5.1) includes all three possible genotypes and a marked DNA 
ladder as a reference. 
 
              
               Figure 5.1: TNF-α restriction enzyme gel for -308 G→A SNP. A = uncut PCR products, B = 












5.2 TNF-α promoter genotype analysis 
Seventy-seven ART-naïve individuals were genotyped for the TNF-α promoter G→A 
SNP, 37 without neuropathy and 40 with symptomatic HIV-DSP.  In the symptomatic 
group, three homozygotes (AA) and seven heterozygotes (GA) for the SNP were 
identified.  This equals a 25% prevalence of the SNP in this group, with an A-allelic 
(non-ancestral) frequency of 16.25%.  In the DSP-free group, two homozygotes (AA) 
and eight heterozygotes (GA) were identified.  This equals a 27% prevalence of the 
SNP with an A-allelic frequency of 16.22% (Table 5.1).   
 
Table 5.1: TNF-α promoter genotype results 
 Symptomatic HIV-DSP No DSP 
Genotype N (%) N (%) 
GG 30 (75) 27 (73) 
GA 7 (17.5) 8 (21.6) 
AA 3 (7.5) 2 (5.4) 
 40 (100) 37 (100) 
A-allelic frequency 16.25% 16.22% 
 
TNF-α promoter -308 genotypes were further investigated for an association with 
symptomatic DSP by comparing the ancestral genotype (GG, referred to as TNF1) to 
the combined non-ancestral genotypes (GA and AA genotypes, collectively referred 
to as TNF2).  No significant difference was demonstrated in the prevalence of the 
SNP between subjects with symptomatic HIV-DSP and those without neuropathy 
(Table 5.2). 
 
Table 5.2: TNF-α promoter classification 
 Symptomatic HIV-DSP No DSP  
Genotype N (%) N (%) p-value 
TNF1 (ancestral) 30 (75) 27 (73) 0.84 















5.3 IL-10 promoter -1082 A→G, -819 C→T and -592 C→A SNPs sequencing 
A total of 60 subjects’ DNA was sequenced, comprising 30 subjects in each of the 
symptomatic HIV-DSP and DSP-free groups.  Figure 5.2 represents the three 
possible genotypes for each of the SNPs. 
 
IL-10 -1082 A→G IL-10 -819 C→T IL-10 592 C→A 
 
Figure 5.2 IL-10 promoter sequence samples. Columns from left to right represent the -1082, -819 
and -592 SNPs.  Rows from top to bottom represent homozygotes (ancestral), heterozygotes and 
homozygotes for the respective polymorphisms. 
 
The results of the three IL-10 promoter genotypes and the allelic frequency of each 
of the non-ancestral alleles are summarized in Table 5.3.  Each of the IL-10 
promoter polymorphisms was further categorized according to ancestral- and non-
ancestral genotypes (similar to TNF-α classification, Table 5.4).  No significant 
difference in any of the IL-10 promoter SNPs were demonstrated between the 













Table 5.3: IL-10 promoter genotyping results 
 Symptomatic HIV-DSP No DSP 
-1082 Genotype N (%) N (%) 
AA 14 (46.7) 10 (33.3) 
AG 13 (43.3) 17 (56.7) 
GG 3 (10) 3 (10) 
 30 (100) 30 (100) 
G-allelic frequency 31.7% 38.3% 
   
-819 genotype N (%) N (%) 
CC 13 (43.3) 16 (53.3) 
CT 17 (56.7) 10 (33.3) 
TT 0 (0) 4 (13.3) 
 30 (100) 30 (100) 
T-allelic frequency 28.3% 30% 
   
-592 genotype N (%) N (%) 
CC 14 (46.7) 16 (53.3) 
CA 16 (53.3) 10 (33.3) 
AA 0 (0) 4 (13.3) 
 30 (100) 30 (100) 
A-allelic frequency 26.7% 30% 
 
 
Table 5.4: IL-10 promoter classification 
Genotype Symptomatic HIV-DSP No DSP p-value 
 N (%) N (%)  
1082-1 (ancestral) 14 10 0.29 
1082-2 16 20 
819-1 (ancestral) 13 16 0.44 
819-2 17 14 
592-1 (ancestral) 14 16 0.61 














5.4 IL-10 promoter haplotype classification 
IL-10 promoter haplotypes in relation to IL-10 production have been defined and 
described previously (see 1.3.5 Expression regulated by genotypes and Table 1.1).  
We explored the frequency of each of these haplotype groups in neuropathy-free 
subjects and in those with symptomatic HIV-DSP, but did show any significant 
differences (p=0.64, Table 5.5).  
 
Table 5.5: IL-10 production by haplotype  
 Symptomatic  HIV-DSP No DSP  
 N (%) N (%) p-value 
High producers 3 (10) 3 (10)  
Intermediate producers 13 (43.3) 17 (56.7)  
Low producers 14 (46.7) 10 (33.3)  
















6.1 Prevalence  
Data from this cross-sectional, observational study in South African urban 
ambulatory subjects confirms that DSP is a common problem in our HIV-infected 
population.  Using a rigorous clinical definition of DSP that requires the presence of 
at least two neuropathic signs, we found an overall DSP prevalence of 49%.  
Moreover, the prevalence of symptomatic DSP almost doubles from 23% in ART-
naïve subjects to 39% in ART-exposed subjects.   
Prevalence estimates of DSP vary substantially depending on the population studied 
and the definition employed to determine neuropathy status.  Prevalence figures 
from selected studies together with the definition of neuropathy used are 
summarized in Table 6.1, and the corresponding DSP prevalence from our study 
using the respective definitions are tabulated for comparison.  By using our 
definition of DSP, the prevalence in this community clinic-based population is higher 
than those of recently published studies from developed and developing 
populations, some of which had similar-sized cohorts to our study (Wright et al., 



















 ≥2 signs any 1 sign ≥2 signs 1 sign
#
 2 signs 
SA study (N=598) 
 
30% 43% 26% 37% 18% 
USA (N=76)
 
(Cherry et al., 2006) 
  49%   
Australian (N=71)
 
(Cherry et al., 2006) 
  55%   
Asia-Pacific (N=640)
  
(Wright et al., 2008) 
   20% 6% 
Thailand (N=100)
 
(Sithinamsuwan et al., 2008) 
 38% 10%   
Indonesia (N=99)
 
(Affandi et al., 2008) 
   34%  
American ART only (N=502)
 
(Hung et al., 2008) 
26%     
* SDSP as defined in this study, symptoms + ≥ any 2 signs (decreased pin ± vibration ± 
reduced/absent ankle reflexes).   
**American Academy of Neurology-SDSP clinical definition recommended for field studies includes 
symptoms + reduced/absent ankle reflexes + decreased sensation (pin or vibration)
   
# 
Cherry et al., 2005. 
 
From the developed countries, an American study with a similar sample size to our 
cohort had a comparable DSP prevalence, although all of their study participants 
were exposed to ART.  Of these subjects, 23% of those exposed to dNRTI therapy 
had DSP
 
compared to 63% of this community-based SA population (Table 6.1) (Hung 
et al., 2008).  Smaller samples from the USA and Australia (Cherry et al., 2006) 
showed higher DSP prevalence figures, but included notably older subjects, which 
possibly accounts for the higher prevalence rates; these study populations also did 
not exclude subjects with known glucose intolerance.   
From developing countries, a multi-centre study spanning the Asia-Pacific region 
found a lower DSP prevalence (20%) amongst a study population comparable to our 
cohort in size and dNRTI use (Wright et al., 2008).  On the other hand, smaller 












figures comparable to ours (Sithinamsuwan et al., 2008, Affandi et al., 2008).  It is 
clear that prevalence figures vary depending on the criteria used for defining 
neuropathy.  To illustrate this point, prevalence figures from this South African 
cohort vary from 18% to 43% according to the different clinical definitions, as 
presented in Table 6.1 (also see 6.6 Small fibre sensory neuropathy study tools).  
 
6.2 Clinical symptoms and signs of DSP 
All the neuropathic signs and symptoms included in the definition of DSP were 
significantly more prevalent in subjects with DSP compared to those without.  
However, symptoms were also reported frequently by individuals who were not 
categorized as having DSP i.e. without at least two neuropathic signs.  Pain was the 
most prevalent DSP symptom affecting nearly half of all individuals with DSP, but 
also reported by a quarter of subjects without DSP.  It is unclear why such a large 
proportion of study participants without a diagnosis of DSP experiences symptoms, 
although it is recognized that our definition excluded subjects who only had 1 
abnormal sign on examination.  Prospective evaluation of ENFD in subjects with 
pain in the absence of symptoms might be useful to define this phenotype, and to 
evaluate the possibility that it may represent a transitional state to developing 
clinically evident neuropathy in susceptible individuals. 
Decreased or absent deep tendon reflexes at the ankle was the most common sign 
in the DSP group, followed by decreased pinprick sensation.  This may be important 
for the use of the BPNS as a screening tool as decreased pinprick sensation is not 
included in the BPNS. 
 
6.3 Risk factors for DSP 
Risk factors in our population not only include advancing age and ART exposure, 
factors previously identified in developed countries (Cherry et al., 2006, Smyth et 
al., 2007), but also a frequent history of previously treated TB infection.  Contrary to 












gross markers of nutritional state such as weight and body mass index, were not 
significantly associated with DSP in this population.  On anthropometric measures, 
waist-to-hip ratio was significantly higher in those with DSP compared to those 
without, but the significance of this is unclear in the absence of association with 
other metabolic markers.   
Although studies have reported that nutritional indices such as decreased serum 
albumin and weight loss are associated with neuropathy (Tagliati et al., 1999; Snider 
et al., 1983, So et al., 1988), the impact of nutritional status on DSP has not been 
systematically studied.  While our study showed no association between DSP and 
macronutritional status as reflected by body weight, BMI, mid-upper arm 
circumference or calf skin fold thickness, micronutrient status may play a role in 
preventing DSP and needs further investigation.   
The indirect consequences of TB infection or its therapy was shown to be 
independently associated with DSP, irrespective of ART treatment status.  TB is a 
common problem in the Western Cape, and this Cape Town-based population’s 
prevalence of previous TB infections is also similar to other cohorts from South 
Africa (Lawn et al., 2006).  A possible reason for an increased association of DSP 
with a history of previous TB may come from the results of a double-blind placebo-
controlled micronutrient supplement study in Tanzanians on TB therapy.  They 
showed a reduced incidence of peripheral neuropathy in those who received 
supplements, irrespective of HIV status (Villamor et al., 2008).  The supplements 
used consisted of vitamins A, B (1, 2, 3, 6, and 12), C, E, folic acid and selenium.  In 
South African primary health care clinics, patients on TB therapy will occasionally 
receive pyridoxine supplementation as isoniazid influences pyrodixine metabolism 
(Standard Treatment Guidelines and Essential Drugs List For South Africa, 2006), 
and two tablets of vitamin B complex per day are usually prescribed for HIV-
infected individuals.  One of the currently-used vitamin B complex tablets (in the 
Western Cape state healthcare sector) provide less than a tenth of the dose of some 
of the vitamin B subgroups compared to that used in the abovementioned study, 
and also do not contain vitamins A, C, E, folic acid or selenium (from the South 












the progress made in the first year of ART-rollout in South Africa showed that 13% 
of ART-clinics experienced stock outs of antiretrovirals, and 32% of clinics 
experienced stock outs of nutritional and vitamin supplements during that year.  A 
further 9% of ART-clinics do not provide nutritional or vitamin supplements at all 
(Stewart and Loveday, 2005).  Our data also suggested a trend towards lower 
vitamin B complex use in subjects with ATN compared to ART-exposed subjects 
without DSP.   
We could not confirm subject height as a risk factor for DSP, as recently found by 
two studies from Australia and Indonesia (Cherry et al., 2008b, Affandi et al., 2008).  
These findings were based on study populations consisting of 13% and 3% females 
respectively, whereas our study had a female preponderance.  
Hepatitis C was previously thought to be a confounder in the diagnosis of HIV-
associated neuropathies, including DSP (Estanislao et al., 2005) but not all studies 
have shown an association with DSP (Cherry et al., 2006, Wright et al., 2008).  In our 
setting (Cape Town), hepatitis C virus infection has very low background prevalence 
ranging from <0.1% in blood donors to 1.6% amongst high risk HIV-infected white 
males who have sex with males (Tucker et al., 1997, Amin et al., 2004).  Although 
we did not record the sexual habits of our study population, hepatitis C infection 
should have a limited impact on our prevalence rate as our study population were 
predominantly female (77%) as generally found in South African cohorts (Lawn et 
al., 2006, Boulle et al., 2007). 
No risk factor with the exception of age differentiated between asymptomatic and 
symptomatic DSP; subjects with symptomatic HIV-associated DSP were significantly 
older than those who were asymptomatic.  Obvious causes of symptomatic 
neuropathy such as alcohol and measure of glucose intolerance were equally 












6.4 Impact of ART and associated ATN 
Antiretroviral therapy is often associated with the risk of developing ATN (Cherry et 
al., 2006, Smyth et al., 2007).  Although overall DSP is associated with ART use in 
this population, the proportions of individuals who are currently using d4T as well 
as those who have ever used d4T previously, were lower in subjects with ATN 
compared to neuropathy-free individuals.  This was consistent with a recently 
published report of a significantly lower ATN rate in dNRTI-exposed subjects 
compared to those not taking dNRTIs (Hung et al., 2008).  This observation may 
reflect judicious avoidance of stavudine-containing regimens in subjects with 
neuropathic symptoms prior to ART initiation, or may suggest an as yet, 
unaccountable factor(s) and requires further longitudinal study. 
We found no evidence of cumulative toxicity of stavudine use based on a similar 
duration of exposure to the drug in the ATN and ATN-free groups, whether you 
consider those on the drug currently or previously.   This observation is also 
consistent with previous reports by several groups in which they conclude that, 
despite an increased risk of developing DSP within the first few months of starting 
on a dNRTI regimen, most subjects tolerated dideoxynucleoside therapy and 
without a late increase in the risk of worsening neuropathy (Hung et al., 2008, 
Cherry et al., 2006, Arenas-Pinto et al., 2008, Schifitto et al., 2005, Simpson et al., 
2006).  Data has shown that the risk of developing DSP peaks at three months of 
exposure to stavudine, where after it decreased (Arenas-Pinto et al., 2008).  Also, 
subjects from our study who had never used stavudine, although comparatively 
few, were as likely to develop DSP as those on stavudine containing regimens.   
The increased risk of developing DSP after initiation of ART raised a question as to 
whether recovery of the host’s immune system is at play.  The immune 
reconstitution syndrome generally manifests in the first three months after 
commencing ART in a spectrum of diseases (Dhasmana et al., 2008).  Attempts have 
been made to define criteria for quantifying  immune recovery, but this is 
frequently not informative as the syndrome can manifest before quantitative 












countries where viral load counts and CD4 counts are frequently missing (in 
Dhasmana et al., 2008).  To explore the possibility of host immune reconstitution as 
a contributory factor in the early development of NRTI-induced DSP (ATN), we used 
an arbitrary definition of immune recovery as a rise in CD4 count of 50 cells/μl 
within the first 6 months after ART commencement, but found no association. 
The risk factors for ATN were similar to DSP overall with increasing age and 
previously treated TB infection identified as independent risk factors for ATN.  As an 
additional risk factor, MCV increase from the pre-ART baseline until follow-up at six 
months associated independently with ATN. The relevance of this finding is still 
unclear and warrants further study.  
Lactate was previously found to associate with ATN although based on a small study 
(Brew et al., 2003), but did not associate with ATN in this study.  A substantial risk of 
hyperlactataemia was previously demonstrated amongst black South African 
women weighing over 75kg on stavudine-based regimens (Boulle et al., 2007), but 
this finding could not be replicated in our study despite the fact that nearly a third 
of female subjects on stavudine weighed more than 75kg.  A notable difference 
however exists in the stavudine dosage as the previously mentioned study was 
conducted on a population using a 40mg twice-daily dose compared to our 
population where the majority of d4T-exposed subjects used 30mg twice a day. 
 
6.5 Quality of life and DSP 
The majority of subjects with symptomatic DSP experienced neuropathic symptoms 
of moderate to severe intensity as measured by the BPNS VAS, indicating its 
importance as a primary health care burden.  Neuropathy has an adverse effect on 
quality of life and pain in the HIV population has been shown to impact upon other 
clinically important parameters such as utilization of health services, affective 
disorders, and functional status (Rosenfeld et al., 1996; Pandya et al., 2005; Rusch 












Our data show that in all dimensions of the EQ-5D there was a tendency for ART to 
show a positive impact on the lives of participants, irrespective of neuropathy 
status.  Although individuals with ATN consistently reported less impairment 
compared to those with HIV-DSP, the difference was only significant in the 
dimension of mobility impairment.  This is largely comparable to the profile of a 
prospectively-studied ART-exposed cohort from the same geographical location and 
culture, which found that health-related quality of life improved over the 12-month 
period following ART initiation (Jelsma et al., 2005).   
The EQ-5D’s dimension of pain/discomfort did not discriminate between subjects 
with or without DSP.  Importantly, poor pain control is estimated to occur in over 
half of the HIV-population being treated for pain (Breitbart et al., 1998).  The low 
use of amitriptyline by our population suggests either poor efficacy in neuropathic 
pain management (Kieburtz et al., 1998) or under-recognition of depression and a 
more generalised perception of discomfort or pain in HIV/AIDS subjects irrespective 
of neuropathy.  Both these scenarios have been encountered in other developing 
nations (Wright et al., 2008) where the burden of disease in conjunction with 
limited health budgets highlights the need for cheap but effective strategies to 
manage patients’ pain. 
We did not show an association between neuropathy and mood, though cultural 
variables may be at play; the EQ-5D has been validated in isiXhosa across all five 
domains, although the concept behind the word “depression” differ in Xhosa 
culture (Jelsma et al., 2004).  To a Xhosa speaker, “depression” is regarded as 
temporary in nature and necessarily associated with a cause, and reported rates in 
the validation study were lower than expected (Jelsma et al., 2004).  Compared to 
the previously mentioned cohort from Cape Town (Jelsma et al. 2005), our study 
population’s response to both the pain/discomfort and depression/anxiety 
dimensions were similar in the ART-exposed subgroups, but was lower in our ART-
naïve subjects compared to those from the reference study.  Another South African 
study found subjects on ART to report less impairment than those awaiting ART, 












programme and possibly comprised subjects with more advanced HIV-infection and 
AIDS (Louwagie et al., 2007). 
In summary, the results of the quality of life assessment did not differentiate 
between individuals with or without DSP.  The EQ-5D is generally used as a tool to 
assess the impact of interventions on health-related quality of life, and confirmed 
that ART had a beneficial impact on most of our HIV-infected study population.   
 
6.6 Small fiber sensory neuropathy study tools 
To our knowledge there are no previous reports of observational, systematic 
examination for DSP on HIV-infected African subjects using validated tools.  
Although selected studies from Africa mention peripheral neuropathy prevalence in 
the context of adverse effects of ART, it is often without reference to the diagnostic 
criteria for DSP that were used (Jamisse et al., 2007, Hawkins et al., 2007).  A recent 
publication mentioned their criteria which included either subjective reporting of 
neuropathic symptoms or the presence of a single neuropathic sign on physician 
examination (Hoffmann et al., 2008).  These cases would therefore include many of 
our current subjects not categorized as DSP. 
The variation in the DSP prevalence figures in this cohort (Table 6.1) depending on 
the clinical definition employed highlights the importance of establishing a stringent 
clinical definition that can be used in field or epidemiological studies, but that has 
been validated against a gold standard reference test such as ENFD determination 
on skin biopsy.  The validation study should be conducted by examiners blinded to 
the result of the reference test, and should be conducted in the population or 
setting where it is intended for use (Benatar, 2006).  Preferably, this definition 
should also be applicable in resource-constraint populations, where even the 
availability of basic instruments such as tuning forks, may be limited.   
A definition for DSP was proposed by England et al. (see 1.1.7.1 Proposed 
definitions) based on a systematic analysis of peer-reviewed literature and 












various definitions for clinical research studies and epidemiologic studies were 
ranked by estimated ordinal likelihood of disease, as different reference standards 
were used in the literature.  However, as pointed out by Benatar (2006) the 
proposed definition was based on diagnostic modalities that overlapped with the 
reference tests used in the studies thereby artificially inflating sensitivity and 
specificity of the tests.  
Little data is available correlating clinical diagnostic tests for DSP in HIV-infected 
populations with a gold standard such as ENFD estimation from skin biopsy.  An 
adapted version of the original BPNS (requiring only 1 sign in the presence of 
symptoms for the diagnosis of SDSP) correlated well with nerve fibre loss in ENFD 
measurements at the distal leg in HIV-associated DSP (Cherry et al., 2005), but did 
not perform well against the TNS as a diagnostic tool (Table 2.3 and Table 2.4).  
Further study is needed to determine which clinical test provides an adequate 
screening tool for the small fibre neuropathy associated with HIV-infection and that 
of ATN. 
 
6.7 Cytokine promoter polymorphism genotyping 
TNF-α promoter -308 G→A SNP:  In this pilot study, we found a background 
frequency of the TNF-α -308 A-allele of 16% in our control (DSP-free) subjects, 
which was similar to the A-allelic frequency of the individuals with symptomatic 
HIV-DSP (16%).  Therefore, no association was found between the presence of the 
TNF2 allele and symptomatic HIV-DSP.  Although the number of subjects in each 
group was relatively small (n=30), it would appear unlikely that a larger cohort 
would find a different result as there were almost no difference in SNP frequency 
between the DSP-free and symptomatic HIV-DSP groups. 
Unexpectedly, the A-allelic frequency was higher in this Xhosa-speaking South 
African cohort than that previously reported in subjects from sub-Saharan Africa, 
comprising mostly Nigerians (Entrez SNP Database).  We also found 6% of our 












on the NCBI SNP database for African populations, but the homozygous individuals 
were evenly distributed between symptomatic HIV-DSP and DSP-free groups.   
Recently published studies from Australia and Indonesia found the frequency of the 
TNF-α promoter -308 A-allele in subjects with DSP to be 13% (Cherry et al., 2008b 
[calculated]) and 10% (Affandi et al., 2008).  These reports were based on small 
study populations (N=55 and 96 respectively), and one study found an insignificant 
increase in representation of the -308 A-allele in subjects with ATN (p=0.12, Cherry 
et al., 2008b).  However, both studies identified the TNF-α -1301 C-allele (non-
ancestral) to be associated with ATN.  A recent study from India found this allele to 
be associated with higher serum levels of TNF-α in malaria-related fever (Sohail et 
al., 2008). They also showed the TNF-α -308 G→A and -1031 T→C SNPs to be in 
linkage disequilibrium in patients with malaria, but not in healthy controls (Sohail et 
al., 2008), and this finding did not seen apparent from the Indonesian study (Affandi 
et al., 2008).   
We did not investigate the TNF-α promoter -308 SNP in association with ATN and 
can therefore not confirm the abovementioned studies’ findings.  We also did not 
investigate the TNF-α -1031 T→C SNP in association with HIV-DSP, as the data 
regarding its significance was only published after we conducted the association 
pilot study.  Haplotype associations varying with ethnicity may be responsible for 
the inconsistent observed responses to genetic polymorphisms (Lu et al., 2008, 
Cherry et al., 2008b, Zabaleta et al., 2008), and warrants further study in African 
populations.  
IL-10 promoter SNPs: Neither of the three IL-10 promoter SNPs, nor the IL-10 
haplotypes as classified according to the previously reported rate of IL-10 
production (Hoffmann et al., 2001), associated with DSP status in this pilot study.  
This South African population’s IL-10 -1082 G-allelic frequency of 35% correlates 
well studies from Zimbabwe  (30%, Erikstrup et al., 2007), as well as that reported 
for African-Americans (36% -41%) on the NCBI SNP database.  The frequencies of 












previously reported in African-American individuals (36% to 54% and 50% to 53% 
respectively) (Entrez SNP Database).   
Our aim with this small pilot study was to ascertain whether a larger study would be 
feasible, but our results suggest against this and the pilot study was therefore not 
expanded. 
 
6.8 Study limitations 
Our study is also limited insofar as we did not evaluate all subjects for other 
possible causes of a distal polyneuropathy, such as a vitamin B12 deficiency.  Poor 
clinic record keeping and poor compliance to governmental protocol with regards 
to blood sampling limited the usefulness of some of the parameters such as viral 
load measurements.   
Our definition of DSP consisted only of clinical measures, without 
electrophysiological or histological confirmation of the diagnosis as these are very 
difficult to perform in field studies.  Although electrophysiological tests are not 
always needed for the diagnosis of DSP, it is useful in the diagnosis of a pure small 
fibre neuropathy.  The cross-sectional nature of this study precluded evaluation of 
whether or not pre-existing HIV-DSP constitutes a risk factor for ATN.  It was also 
not possible to accurately establish the prevalence of ATN, as ART-exposed 
individuals could have either ATN or HIV-DSP, and the temporal relationship 
between ART initiation and possible symptom development in our population 
warrants longitudinal investigation. 
 
6.9 Conclusions 
In conclusion, we found that DSP is a frequent and clinically significant problem in a 
HIV-infected African community clinic-based population, where its frequency 
increases with antiretroviral therapy, age and previously treated TB infection, and is 












associations of HIV-DSP in populations from the developed countries such as male 
gender (Morgello et al., 2004) and subject height (Affandi et al., 2008, Cherry et al., 
2008), were not replicable in this African population.  This study present novel 
results showing that neuropathy status was not associated with duration of 
stavudine exposure in Africans, and with careful avoidance of stavudine-containing 
regimens in older subjects, especially with a history of prior TB infection, the 
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  Health Questionnaire 
 















By placing a tick in one box in each group below, please indicate which statements best 




I have no problems in walking about  
I have some problems in walking about  
I am confined to bed  
 
Self-Care 
I have no problems with self-care  
I have some problems washing or dressing myself  
I am unable to wash or dress myself  
 
Usual Activities (e.g. work, study, housework, family or 
leisure activities) 
I have no problems with performing my usual activities  
I have some problems with performing my usual activities  
I am unable to perform my usual activities  
 
Pain/Discomfort 
I have no pain or discomfort  
I have moderate pain or discomfort  
I have extreme pain or discomfort  
 
Anxiety/Depression 
I am not anxious or depressed  
I am moderately anxious or depressed  
I am extremely anxious or depressed  
 
Compared with my general 
level of health over the past 12 months, 
my state of health today is: 
 
Better   PLEASE TICK 
Much the same  ONE 


















To help people say how good or bad their state of 
health is, we have drawn a scale on which the best 
state you can imagine is marked 100 and the worst 
state you can imagine is marked 0. 
 
We would like you to indicate on this scale, in your 
opinion, how good or bad your own health is today. 
Please do this by drawing a line from the box below 
to whichever point on the scale indicates how good 




















































IL-10 promoter sequencing: comparing 2 reverse primers 
The 2 reverse primers designed for the IL-10 sequencing reaction were compared by using 
both primers on PCR product amplified from the same subject’s DNA using reverse primer 1 
(see 3.10.1 Primer design).  Both primers produced readable seque ces, but sequencing 
with reverse primer 1 resulted in more background noise and occasional misreads.  It was 
therefore decided to do internal sequencing with reverse primer 2 for all sequencing 
reactions.  
 
Figure C.1: Sequences of reverse primer 1 (left) and reverse primer 2 (right) 
 
